

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3981	514/54	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:40
L2	2	I1 and (tissue NEAR volume NEAR increase\$)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:44
L3	553	I1 and alginate	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:46
L4	4	I3 and (inject\$ NEAR tissue)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:46
L5	440	424/70.13	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:48
L6	44	I5 and alginate	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:48

EAST Search History

L7	0	I6 and (inject\$ NEAR tissue)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:49
L8	61315	alginate	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:51
L9	781	I8 and (inject\$ NEAR tissue)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:51
L10	728	I9 and (augment\$ or volume)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:51
L11	719	I10 and increas\$	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:51
L12	15	I8 and (tissue NEAR volume NEAR increase\$)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:53

EAST Search History

L13	16	I8 and (tissue NEAR volume NEAR increas\$)	US-PGPU B; USPAT; EPO; JPO; DERWEN T	OR	OFF	2008/01/29 10:54
-----	----	---	--	----	-----	---------------------

dis hist

(FILE 'HOME' ENTERED AT 11:00:15 ON 29 JAN 2008)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPATOLD, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, BIOSIS, EMBASE, MEDLINE' ENTERED AT 11:00:37 ON 29 JAN 2008

L1	162242 S ALGINATE
L2	45390 S L1 AND TISSUE
L3	28965 S L2 AND (AUGMENT? OR VOLUME)
L4	26601 S L3 AND INCREAS?
L5	11750 S L4 AND (CROSS(A) LINK?)
L6	2611 S L5 AND MICROPARTIC?
L7	2357 S L6 AND (CALCIUM OR BARIUM)
L8	2094 S L7 AND (SKIN OR MUSCLE OR SPHINCTER)
L9	1794 S L8 AND (EDTA OR CITRATE)
L10	1767 S L9 AND GEL
L11	800 S L9 AND HYDROGEL
L12	501 S L11 AND (SUBCUTANEOUS(S) INJECTION)
L13	133 S L12 AND (ADHESION(S) PEPTIDE)
L14	421 S L12 AND (ANTIBIOTIC OR STREPTOMYCIN)
L15	400 S L14 AND (ENGINEER? OR REPLACEMENT)
L16	333 S L15 AND ADHESION
L17	21 S L16 AND URON?

FILE 'CAPLUS' ENTERED AT 11:21:12 ON 29 JAN 2008

L18	63 S REINER ROLAND/AU
L19	1 S L18 AND ALGINATE
L20	7 S GEIGLE PETER/AU
L21	2 S GLOCKNER HERMA/AU
L22	2 S THURMER FRANK/AU

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE timeliness enhanced
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:00:15 ON 29 JAN 2008

=> file polymer biosis embase medline
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'APOLLIT' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (c) 2008 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 11:00:37 ON 29 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (c) 2008 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 11:00:37 ON 29 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 11:00:37 ON 29 JAN 2008
Compendex Compilation and Indexing (C) 2008
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 11:00:37 ON 29 JAN 2008
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2008)

FILE 'PASCAL' ENTERED AT 11:00:37 ON 29 JAN 2008
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 11:00:37 ON 29 JAN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 11:00:37 ON 29 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 11:00:37 ON 29 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:00:37 ON 29 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 11:00:37 ON 29 JAN 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:00:37 ON 29 JAN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:00:37 ON 29 JAN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 11:00:37 ON 29 JAN 2008

=> s alginate
L1 162242 ALGINATE

=> s l1 and tissue
L2 45390 L1 AND TISSUE

=> s l2 and (augment? or volume)
24 FILES SEARCHED...
L3 28965 L2 AND (AUGMENT? OR VOLUME)

=> s l3 and increas?
16 FILES SEARCHED...
L4 26601 L3 AND INCREAS?

=> s l4 and (cross(a)link?)

20 FILES SEARCHED...

L5 11750 L4 AND (CROSS(A) LINK?)

=> s 15 and micropartic?

L6 2611 L5 AND MICROPARTIC?

=> s 16 and (calcium or barium)

L7 2357 L6 AND (CALCIUM OR BARIUM)

=> s 17 and (skin or muscle or sphincter)

L8 2094 L7 AND (SKIN OR MUSCLE OR SPHINCTER)

=> s 18 and (EDTA or citrate)

L9 1794 L8 AND (EDTA OR CITRATE)

=> s 19 and gel

L10 1767 L9 AND GEL

=> s 19 and hydrogel

L11 800 L9 AND HYDROGEL

=> s 111 and (subcutaneous(s)injection)

18 FILES SEARCHED...

L12 501 L11 AND (SUBCUTANEOUS(S) INJECTION)

=> s 112 and (adhesion(s)peptide)

12 FILES SEARCHED...

L13 133 L12 AND (ADHESION(S) PEPTIDE)

=> s 112 and (antibiotic or streptomycin)

L14 421 L12 AND (ANTIBIOTIC OR STREPTOMYCIN)

=> s 114 and (engineer? or replacement)

L15 400 L14 AND (ENGINEER? OR REPLACEMENT)

=> s 115 and adhesion

L16 333 L15 AND ADHESION

=> s 116 and uron?

L17 21 L16 AND URON?

=> dis 117 1-21 bib abs

L17 ANSWER 1 OF 21 USPATFULL on STN

AN 2007:4817 USPATFULL

TI 2-O sulfatase compositions and methods of hydrolyzing therewith

IN Sasisekharan, Ram, Bedford, MA, UNITED STATES
Myette, James, Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES

PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)

PI US 2007004012 A1 20070104
US 7247445 B2 20070724

AI US 2006-432824 A1 20060511 (11)

RLI Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING

PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 3939

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 21 USPATFULL on STN

AN 2006:340892 USPATFULL

TI 2-O sulfatase compositions and methods of degradation therewith

IN Sasisekharan, Ram, Bedford, MA, UNITED STATES

Myette, James, Belmont, MA, UNITED STATES

Shriver, Zachary, Boston, MA, UNITED STATES

Venkataraman, Ganesh, Bedford, MA, UNITED STATES

PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)

PI US 2006292673 A1 20061228

AI US 2006-433340 A1 20060511 (11)

RLI Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING

PRAI JP 2003-271653 20030707

US 2003-438810P 20030108 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 4046

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 3 OF 21 USPATFULL on STN

AN 2006:340874 USPATFULL

TI 2-O sulfatase compositions and methods of analyzing therewith

IN Sasisekharan, Ram, Bedford, MA, UNITED STATES

Myette, James, Belmont, MA, UNITED STATES

Shriver, Zachary, Boston, MA, UNITED STATES

Venkataraman, Ganesh, Bedford, MA, UNITED STATES

PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES

(U.S. corporation)
PI US 2006292655 A1 20061228
AI US 2006-433228 A1 20060511 (11)
RLI Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 4004

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 21 USPATFULL on STN
AN 2006:340350 USPATFULL
TI 2-O sulfatase nucleic acid compositions
IN Sasisekharan, Ram, Bedford, MA, UNITED STATES
Myette, James, Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006292130 A1 20061228
AI US 2006-433224 A1 20060511 (11)
RLI Division of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 3977

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase

and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 21 USPATFULL on STN
AN 2006:215733 USPATFULL
TI Delta 4,5 glycuronidase nucleic acid compositions
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006183891 A1 20060817
AI US 2006-402491 A1 20060411 (11)
RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2584
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ 4,5 glycuronidase, related compositions,
and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 21 USPATFULL on STN
AN 2006:215557 USPATFULL
TI Compositions of low molecular weight heparin produced with modified
heparinase III
IN Liu, Dongfang, Yorktown Heights, NY, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006183713 A1 20060817
AI US 2006-406215 A1 20060418 (11)
RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat.
No. US 6869789
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to heparinase III and mutants thereof. Modified
forms of heparinase III having reduced enzymatic activity which are
useful for a variety of purposes, including sequencing of heparin-like
glycosaminoglycans (HLGAGs), removing active heparan sulfate from a

solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 21 USPATFULL on STN

AN 2006:214581 USPATFULL

TI Methods for preparing low molecular weight heparin with modified heparinase III

IN Liu, Dongfang, Yorktown Heights, NY, UNITED STATES

Pojasek, Kevin, Cambridge, MA, UNITED STATES

Shriver, Zachary, Boston, MA, UNITED STATES

Holley, Kristine, Boston, MA, UNITED STATES

El-Shabrawi, Yosuf, Graz, AUSTRIA

Venkataraman, Ganesh, Bedford, MA, UNITED STATES

Sasisekharan, Ram, Bedford, MA, UNITED STATES

PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)

PI US 2006182734 A1 20060817

AI US 2006-406214 A1 20060418 (11)

RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat.
No. US 6869789

PRAI US 2000-187846P 20000308 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 17 Drawing Page(s)

LN.CNT 2988

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 21 USPATFULL on STN

AN 2006:208914 USPATFULL

TI Delta 4,5 glycuronidase and methods of cleaving therewith

IN Myette, James R., Belmont, MA, UNITED STATES

Shriver, Zachary, Boston, MA, UNITED STATES

Venkataraman, Ganesh, Bedford, MA, UNITED STATES

Sasisekharan, Ram, Bedford, MA, UNITED STATES

McLean, Maitland W., Orkney, UNITED KINGDOM

PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)

PI US 2006177911 A1 20060810

AI US 2006-403096 A1 20060411 (11)

RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING

PRAI US 2002-377488P 20020503 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ 4,5 glycuronidase, related compositions,
and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 9 OF 21 USPATFULL on STN
AN 2006:208913 USPATFULL
TI Delta 4,5 glycuronidase and methods of hydrolyzing therewith
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006177910 A1 20060810
AI US 2006-402542 A1 20060411 (11)
RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ 4,5 glycuronidase, related compositions,
and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 21 USPATFULL on STN
AN 2006:208888 USPATFULL
TI Delta 4,5 glycuronidase and methods of analyzing therewith
IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006177885 A1 20060810
AI US 2006-402543 A1 20060411 (11)
RLI Division of Ser. No. US 2003-429921, filed on 5 May 2003, PENDING
PRAI US 2002-377488P 20020503 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 2617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to Δ 4,5 glycuronidase, related compositions,

and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 21 USPATFULL on STN
AN 2006:79937 USPATFULL
TI Heparinase III and methods of specifically cleaving therewith
IN Liu, Dongfang, Yorktown Heights, NY, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Bedford, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 2006067928 A1 20060330
AI US 2005-187571 A1 20050722 (11)
RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat.
No. US 6869789
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2993

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 21 USPATFULL on STN
AN 2005:268086 USPATFULL
TI Heparinase III HLGAG fragments and uses thereof
IN Liu, Dongfang, Westborough, MA, UNITED STATES
Pojasek, Kevin, Boston, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Lincoln, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES,
02139 (U.S. corporation)
PI US 2005233402 A1 20051020
AI US 2004-967067 A1 20041014 (10)
RLI Division of Ser. No. US 2002-291337, filed on 8 Nov 2002, PENDING
Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, GRANTED, Pat.
No. US 6869789
PRAI US 2000-187846P 20000308 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,

BOSTON, MA, 02210-2211, US

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN 17 Drawing Page(s)

LN.CNT 3112

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 21 USPATFULL on STN

AN 2005:138619 USPATFULL

TI Heterocyclic compounds and methods of making and using thereof

IN Rao, Yeleswarapu Koteswar, Hyderabad, INDIA

Pal, Manojit, Hyderabad, INDIA

Sharma, Vedula Manohar, Hyderabad, INDIA

Venkateswarlu, Akella, Hyderabad, INDIA

Pillarisetti, Ram, Norcross, GA, UNITED STATES

PI US 2005119269 A1 20050602

AI US 2004-976284 A1 20041028 (10)

PRAI IN 2003-8612003 20031028

US 2004-610163P 20040915 (60)

DT Utility

FS APPLICATION

LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA,
30357-0037, US

CLMN Number of Claims: 59

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 13564

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 21 USPATFULL on STN

AN 2005:43648 USPATFULL

TI 2-O sulfatase compositions and related methods

IN Sasisekharan, Ram, Lincoln, MA, UNITED STATES

Myette, James R., Belmont, MA, UNITED STATES

Shriver, Zachary, Boston, MA, UNITED STATES

Venkataraman, Ganesh, Waltham, MA, UNITED STATES

PA Massachusetts Institute of Technology, Cambridge, MA (U.S. corporation)

PI US 2005037376 A1 20050217

US 7270815 B2 20070918

AI US 2004-753761 A1 20040107 (10)

PRAI JP 2003-271653 20030707

US 2003-438810P 20030108 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 4010

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 21 USPATFULL on STN

AN 2004:120066 USPATFULL

TI Delta 4, 5 glycuronidase and uses thereof

IN Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES
McLean, Maitland W., Orkney, UNITED KINGDOM

PI US 2004091471 A1 20040513

US 2005214276 A9 20050929

AI US 2003-429921 A1 20030505 (10)

PRAI US 2002-377488P 20020503 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
BOSTON, MA, 02210-2211

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 10 Drawing Page(s)

LN.CNT 2709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to Δ 4,5 glycuronidase, related compositions, and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 21 USPATFULL on STN

AN 2003:145884 USPATFULL

TI Heparinase III and uses thereof

IN Liu, Dongfang, Framingham, MA, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Cambridge, MA, UNITED STATES
Venkataraman, Ganesh, Woburn, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES

PI US 2003099628 A1 20030529

AI US 2002-291337 A1 20021108 (10)

RLI Division of Ser. No. US 2001-802285, filed on 8 Mar 2001, PENDING

PRAI US 2000-187846P 20000308 (60)

DT Utility

FS APPLICATION

LREP Helen C. Lockhart, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue,
Boston, MA, 02210
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 3157

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase II having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 21 USPATFULL on STN

AN 2002:227642 USPATFULL

TI Heparinase III and uses thereof

IN Liu, Dongfang, Framingham, MA, UNITED STATES
Pojasek, Kevin, Cambridge, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Holley, Kristine, Boston, MA, UNITED STATES
El-Shabrawi, Yosuf, Graz, AUSTRIA
Venkataraman, Ganesh, Wallham, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES

PI US 2002122793 A1 20020905

US 6869789 B2 20050322

AI US 2001-802285 A1 20010308 (9)

PRAI US 2000-187846P 20000308 (60)

DT Utility

FS APPLICATION

LREP Helen C. Lockhart, c/o Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210

CLMN Number of Claims: 60

ECL Exemplary Claim: 1

DRWN 15 Drawing Page(s)

LN.CNT 3154

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 21 USPAT2 on STN

AN 2007:4817 USPAT2

TI 2-O sulfatase compositions and methods of hydrolyzing therewith

IN Sasisekharan, Ram, Bedford, MA, UNITED STATES
Myette, James R., Waltham, MA, UNITED STATES
Shriver, Zachary, Cambridge, MA, UNITED STATES
Venkataraman, Ganesh, Bedford, MA, UNITED STATES

PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)

PI US 7247445 B2 20070724

AI US 2006-432824 20060511 (11)
RLI Continuation of Ser. No. US 2004-753761, filed on 7 Jan 2004, PENDING
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saidha, Tekchand
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 5125

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 21 USPAT2 on STN
AN 2005:43648 USPAT2
TI 2-O sulfatase compositions and related methods
IN Sasisekharan, Ram, Lincoln, MA, UNITED STATES
Myette, James R., Belmont, MA, UNITED STATES
Shriver, Zachary, Boston, MA, UNITED STATES
Venkataraman, Ganesh, Waltham, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES
(U.S. corporation)
PI US 7270815 B2 20070918
AI US 2004-753761 20040107 (10)
PRAI JP 2003-271653 20030707
US 2003-438810P 20030108 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Saidha, Tekchand
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 4158

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to 2-O sulfatase and uses thereof. In particular, the invention relates to recombinantly produced 2-O sulfatase, functional variants and nucleic acid molecules that encode these molecules. The invention also provides methods of using 2-O sulfatase for a variety of purposes, including degrading and analyzing glycosaminoglycans (GAGs) present in a sample. For instance, 2-O sulfatase may be used for determining the purity, identity, composition and sequence of glycosaminoglycans present in a sample. The invention also relates to methods of inhibiting angiogenesis and cellular proliferation as well as methods for treating cancer, neurodegenerative disease, atherosclerosis and microbial infection using 2-O sulfatase and/or GAG fragments produced by degradation with 2-O sulfatase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 21 USPAT2 on STN
 AN 2004:120066 USPAT2
 TI Delta 4, 5 glycuronidase and uses thereof
 IN Myette, James R., Belmont, MA, UNITED STATES
 Shriver, Zachary, Cambridge, MA, UNITED STATES
 Venkataraman, Ganesh, Bedford, MA, UNITED STATES
 Sasisekharan, Ram, Cambridge, MA, UNITED STATES
 McLean, Maitland W., Orkney, UNITED KINGDOM
 PI US 2005214276 A9 20050929
 AI US 2003-429921 A1 20030505 (10)
 PRAI US 2002-377488P 20020503 (60)
 DT Utility
 FS APPLICATION
 LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,
 BOSTON, MA, 02210-2211, US
 CLMN Number of Claims: 49
 ECL Exemplary Claim: 1
 DRWN 10 Drawing Page(s)
 LN.CNT 2696
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to A4,5 glycuronidase, related compositions,
 and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 21 USPAT2 on STN
 AN 2002:227642 USPAT2
 TI Heparinase III and uses thereof
 IN Liu, Dongfang, Westborough, MA, United States
 Pojasek, Kevin, Boston, MA, United States
 Shriver, Zachary, Boston, MA, United States
 Holley, Kristine, Boston, MA, United States
 El-Shabrawi, Yosuf, Graz, AUSTRIA
 Venkataraman, Ganesh, Waltham, MA, United States
 Sasisekharan, Ram, Lincoln, MA, United States
 PA Massachusetts Institute of Technology, Cambridge, MA, United States
 (U.S. corporation)
 PI US 6869789 B2 20050322
 AI US 2001-802285 20010308 (9)
 PRAI US 2000-187846P 20000308 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Swope,
 Sheridan L.
 LREP Wolf, Greenfield & Sacks, P.C.
 CLMN Number of Claims: 10
 ECL Exemplary Claim: 1
 DRWN 28 Drawing Figure(s); 17 Drawing Page(s)
 LN.CNT 3359
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to heparinase III and mutants thereof. Modified
 forms of heparinase III having reduced enzymatic activity which are
 useful for a variety of purposes, including sequencing of heparin-like
 glycosaminoglycans (HLGAGs), removing active heparan sulfate from a
 solution, inhibition of angiogenesis, etc. have been discovered
 according to the invention. The invention in other aspects relates to
 methods of treating cancer and inhibiting tumor cell growth and/or
 metastasis using heparinase III, or products produced by enzymatic
 cleavage by heparinase III of HLGAGs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis 113 1-133 bib abs

L13 ANSWER 1 OF 133 USPATFULL on STN
AN 2008:5040 USPATFULL
TI METHODS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING
PEPTIDES FOR TREATING AND PREVENTING OBESITY
IN Quay, Steven C., Woodinville, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2008004218 A1 20080103
AI US 2006-563587 A1 20061127 (11)
RLI Division of Ser. No. US 2004-869649, filed on 16 Jun 2004, GRANTED, Pat.
No. US 7186692 Continuation-in-part of Ser. No. US 2003-745069, filed on
23 Dec 2003, GRANTED, Pat. No. US 7186691 Continuation-in-part of Ser.
No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
PRAI US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL,
WA, 98021-7266, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treating obesity, inducing weight-loss, or inducing satiety
in a mammal comprising administering intranasally to the mammal a
therapeutically effective amount of a pharmaceutical composition
comprising PYY(3-36), a phosphatidylcholine or diglyceride, and a
cyclodextrin, wherein the phosphatidylcholine or diglyceride and the
cyclodextrin are present in an amount sufficient to enhance epithelial
permeation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 133 USPATFULL on STN
AN 2007:334990 USPATFULL
TI HUMAN CDNAS AND PROTEINS AND USES THEREOF
IN BEJANIN, STEPHANE, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PI US 2007292885 A1 20071220
AI US 2007-831468 A1 20070731 (11)
RLI Continuation of Ser. No. US 2004-838854, filed on 3 May 2004, GRANTED,
Pat. No. US 7291495 Division of Ser. No. US 2001-489, filed on 14 Nov
2001, GRANTED, Pat. No. US 6794363 Division of Ser. No. US 2001-924340,
filed on 6 Aug 2001, GRANTED, Pat. No. US 7074901
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX
142950, GAINESVILLE, FL, 32614-2950, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 26802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides polynucleotides and polypeptides encoding an isolated amyloid inhibitor protein (APIP) and compositions thereof. The polypeptides of the subject invention can be used to inhibit the catabolism or sequential cleavage of amyloid beta precursor protein (APP) by sequential cleavage of APP by beta secretase and gamma secretase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 133 USPATFULL on STN
AN 2007:315688 USPATFULL
TI COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF PEPTIDE YY FOR TREATING OBESITY
IN Quay, Steven C., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2007275893 A1 20071129
AI US 2006-561331 A1 20061117 (11)
RLI Division of Ser. No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12004

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions comprising PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the PYY(3-36) is present in an amount effective to alleviate one or more symptom(s) of obesity in a subject, and the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 133 USPATFULL on STN
AN 2007:302266 USPATFULL
TI Methods of Therapy and Diagnosis Using Targeting of Cells that Express Killer Cell Immunoglobulin like Receptor like Proteins
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
PA NUVELO, INC., San Carlos, CA, UNITED STATES, 94070 (U.S. corporation)
PI US 2007264261 A1 20071115
AI US 2007-766911 A1 20070622 (11)
RLI Division of Ser. No. US 2004-962127, filed on 8 Oct 2004, PENDING
Continuation-in-part of Ser. No. WO 2004-US11171, filed on 13 Apr 2004,
PENDING Continuation-in-part of Ser. No. US 2003-727012, filed on 2 Dec 2003, ABANDONED
Continuation-in-part of Ser. No. US 2003-414539, filed on 14 Apr 2003, ABANDONED
DT Utility
FS APPLICATION
LREP NUVELO, INC, 201 INDUSTRIAL ROAD, SUITE 310, SAN CARLOS, CA, 94070, US
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 7979

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with

KIRHy protein-expressing cells, such as acute myelogenous leukemia (AML), are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 133 USPATFULL on STN
AN 2007:265460 USPATFULL
TI INTRANASAL PYY FORMULATIONS WITH IMPROVED TRANSMUCOSAL PHARMACOKINETICS
IN Costantino, Henry R., Woodinville, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
Cohen, Annemarie Stoudt, Kirkland, WA, UNITED STATES
Sileno, Anthony P., Brookhaven Hamlet, NY, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)
PI US 2007232537 A1 20071004
AI US 2006-613109 A1 20061219 (11)
PRAI US 2005-751598P 20051219 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3512

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB What is described is an aqueous Y2 receptor-binding peptide formulation for enhanced intranasal delivery of a Y2 receptor-binding peptide, comprising said Y2 receptor-binding peptide, a buffer salt, and having a pH between about 3.0 and about 6.0, wherein said buffer salt comprises a net single ionogenic moiety with a pK.sub.a within two pH units of the pH of the formulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 133 USPATFULL on STN
AN 2007:243758 USPATFULL
TI PEPTIDE YY FORMULATIONS HAVING INCREASED STABILITY AND RESISTANCE TO MICROBIAL AGENTS
IN Costantino, Henry R., Woodinville, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
Cohen, Annemarie Stoudt, Kirkland, WA, UNITED STATES
PI US 2007213270 A1 20070913
AI US 2005-570223 A1 20050616 (11)
WO 2005-US21377 20050616
20061207 PCT 371 date
PRAI US 2004-580329P 20040616 (60)
US 2004-580310P 20040616 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 79
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 4216

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY (PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) wherein the formulations have increased resistance to microbial contamination and is comprised of a Y2 receptor-binding peptide, water, a cyclodextrin and sodium benzoate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 133 USPATFULL on STN
AN 2007:225337 USPATFULL
TI COMPOSITIONS FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES
IN Quay, Steven C., Woodinville, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Natestech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2007197437 A1 20070823
AI US 2006-561825 A1 20061120 (11)
RLI Division of Ser. No. US 2003-745069, filed on 23 Dec 2003, GRANTED, Pat. No. US 7186691 Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 5390

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions comprising a PYY peptide, a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 133 USPATFULL on STN
AN 2007:224799 USPATFULL
TI POLYNUCLEOTIDES ENCODING A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR SPLICE VARIANT, HGPRBMY29SV2
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PI US 2007196897 A1 20070823
US 7276354 B2 20071002
AI US 2005-71761 A1 20050303 (11)
RLI Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, GRANTED, Pat. No. US 7049096
PRAI US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
US 2001-288468P 20010503 (60)
US 2001-300619P 20010625 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-20
DRWN 36 Drawing Page(s)

LN.CNT 19968

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 133 USPATFULL on STN

AN 2007:211227 USPATFULL

TI ENHANCED MUCOSAL ADMINISTRATION OF NEUROPROTECTIVE PEPTIDES

IN Costantino, Henry R., Woodinville, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)

PI US 2007185035 A1 20070809

AI US 2006-614534 A1 20061221 (11)

PRAI US 2005-753968P 20051223 (60)

DT Utility

FS APPLICATION

LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-7266, US

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3218

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation for intranasal delivery of a neuroprotective peptide, comprising an aqueous mixture of a peptide having the sequence NAPVSIPQ or a pharmaceutically acceptable salt thereof, a solubilizing agent, a chelator, and a surface active agent. The formulation can contain a peptide salt or mucosal delivery-enhancing agent which increases the amount of neuroprotective peptide reaching the therapeutic target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 133 USPATFULL on STN

AN 2007:203434 USPATFULL

TI Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunoglobulin folds, BGS2, 3 and 4 and variants thereof

IN Wu, Shujian, Langhorne, PA, UNITED STATES

Krystek, Stanley R. JR., Ringoes, NJ, UNITED STATES

Lee, Liana, San Francisco, CA, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES

Cheng, Janet D., Seattle, WA, UNITED STATES

PA Bristol-Myers Squibb Company (U.S. corporation)

PI US 2007178088 A1 20070802

AI US 2007-726220 A1 20070321 (11)

RLI Division of Ser. No. US 2002-193477, filed on 11 Jul 2002, GRANTED, Pat. No. US 7223558

PRAI US 2001-304888P 20010711 (60)

US 2002-372147P 20020412 (60)

DT Utility

FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX
4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 18750

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 133 USPATFULL on STN
AN 2007:184570 USPATFULL
TI A DEVICE FOR ENHANCED EPITHELIAL PERMEATION OF Y2 RECEPTOR-BINDING PEPTIDES
IN Quay, Steven C., Woodinville, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Natestech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2007161563 A1 20070712
AI US 2006-562913 A1 20061122 (11)
RLI Division of Ser. No. US 2004-780325, filed on 17 Feb 2004, PENDING
Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, GRANTED,
Pat. No. US 7186691 Continuation-in-part of Ser. No. US 2002-322266,
filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL,
WA, 98021-7266, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 5557

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical device comprising a composition comprising an aqueous solution of PYY(3-36), a cyclodextrin, and a compound selected from phosphatidylcholine or diglyceride, wherein the cyclodextrin and the compound selected from phosphatidylcholine or diglyceride are present in an amount sufficient to enhance epithelial permeation, and wherein the composition is present in a container; and an actuator fluidly connected to the container, wherein the actuator has a tip which defines a passage through which the solution is ejected to produce a spray of the solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 133 USPATFULL on STN

AN 2007:154119 USPATFULL
 TI Polymer particles for delivery of macromolecules and methods of use
 IN Turnell, William D., San Diego, CA, UNITED STATES
 Landis, Geoffrey C., Carlsbad, CA, UNITED STATES
 Gomurashvili, Zaza D., La Jolla, CA, UNITED STATES
 Li, Hong, San Diego, CA, UNITED STATES
 DeFife, Kristin, San Diego, CA, UNITED STATES
 Vassilev, Vassil P., San Diego, CA, UNITED STATES
 Yuan, Yumin, San Diego, CA, UNITED STATES
 PA MediVas, LLC, San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
 PI US 2007134332 A1 20070614
 AI US 2006-603660 A1 20061121 (11)
 PRAI US 2006-796067P 20060427 (60)
 US 2005-738769P 20051121 (60)
 DT Utility
 FS APPLICATION
 LREP DLA PIPER US LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA,
 92121-2133, US
 CLMN Number of Claims: 71
 ECL Exemplary Claim: 1
 DRWN 9 Drawing Page(s)
 LN.CNT 3498
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides biodegradable polymer particle delivery
 compositions for delivery of macromolecular biologics, for example in
 crystal form, based on polymers, such as polyester amide (PEA),
 polyester urethane (PEUR), and polyester urea (PEU) polymers, which
 contain amino acids in the polymer. The polymer particle delivery
 compositions can be formulated either as a liquid dispersion or a
 lyophilized powder of polymer particles containing bound water molecules
 with the macromolecular biologics, for example insulin, dispersed in the
 particles. Bioactive agents, such as drugs, polypeptides, and
 polynucleotides can also be delivered by using particles sized for
 local, oral, mucosal or circulatory delivery. Methods of delivering a
 macromolecular biologic with substantial native activity to a subject,
 for example orally, are also included.

 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L13 ANSWER 13 OF 133 USPATFULL on STN
 AN 2007:148203 USPATFULL
 TI COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE
 IN Quay, Steven C., Seattle, WA, UNITED STATES
 Brandt, Gordon, Issaquah, WA, UNITED STATES
 Kleppe, Mary S., Snohomish, WA, UNITED STATES
 MacEvilly, Conor J., Seattle, WA, UNITED STATES
 PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
 PI US 2007129299 A1 20070607
 AI US 2006-467509 A1 20060825 (11)
 RLI Division of Ser. No. US 2004-768288, filed on 30 Jan 2004, GRANTED, Pat.
 No. US 7157426 Continuation of Ser. No. US 2003-745069, filed on 23 Dec
 2003, GRANTED, Pat. No. US 7186691 Continuation-in-part of Ser. No. US
 2002-322266, filed on 17 Dec 2002, GRANTED, Pat. No. US 7166575
 PRAI WO 2003-US40538 20031217
 US 2003-493226P 20030807 (60)
 US 2003-501170P 20030908 (60)
 US 2003-510785P 20031010 (60)
 US 2003-517290P 20031104 (60)
 US 2003-518812P 20031110 (60)
 DT Utility
 FS APPLICATION
 LREP NASTECH PHARMACEUTICAL COMPANY INC, 3830 MONTE VILLA PARKWAY, BOTHELL,
 WA, 98021-7266, US
 CLMN Number of Claims: 29

ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 5937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions are described comprising PYY(3-36) (SEQ ID NO: 2), a solubilizing agent, a lipid, a polyol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 133 USPATFULL on STN
AN 2007:140890 USPATFULL
TI Rhamnose-inducible expression systems and methods
IN Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2007122881 A1 20070531
AI US 2006-580095 A1 20061011 (11)
RLI Division of Ser. No. US 2002-156902, filed on 28 May 2002, GRANTED, Pat. No. US 7183105 Division of Ser. No. US 2002-154951, filed on 24 May 2002, ABANDONED
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 27475

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Rhamnose-inducible expression constructs are described. The expression constructs may be either episomal or chromosomal and may include at least one rhamnose-inducible regulatory element expressing a regulatory protein and at least one promoter that is inducible by the regulatory protein. An open reading frame expressing a protein of interest may be placed under control of the promoter. Also described are optimized Shine-Dalgarno sequences for use with the promoter.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 133 USPATFULL on STN
AN 2007:55442 USPATFULL
TI Self-assembled endovascular structures
IN Helmus, Michael N., Worcester, MA, UNITED STATES
PI US 2007048383 A1 20070301
AI US 2005-211809 A1 20050825 (11)
DT Utility
FS APPLICATION
LREP MAYER & WILLIAMS PC, 251 NORTH AVENUE WEST, 2ND FLOOR, WESTFIELD, NJ, 07090, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the formation of structures in situ through the principles of ligand binding. These structures are efficacious, for example, for tissue repair as well as for short- and long-term disease and condition management. According to one aspect of the invention, an injectable composition comprising self-assembling nanoparticles is provided. The self-assembling nanoparticles include: (a) a nanoparticle portion, (b) tissue binding ligands attached to the nanoparticle portion, which cause preferential binding and accumulation of the nanoparticles at one or more targeted tissue locations upon injection of the

composition into the body, and (c) first and second interparticle binding ligands attached to the nanoparticle portion, which cause interparticle binding upon injection of the composition into the body.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 133 USPATFULL on STN
AN 2007:36348 USPATFULL
TI Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Ringoes, NJ, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PA Bristol-Myers Squibb Company (U.S. corporation)
PI US 2007031888 A1 20070208
AI US 2006-582264 A1 20061017 (11)
RLI Division of Ser. No. US 2004-882761, filed on 1 Jul 2004, PENDING
Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, GRANTED, Pat. No. US 6858407
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1-23
DRWN 16 Drawing Page(s)
LN.CNT 14307

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 133 USPATFULL on STN
AN 2006:333477 USPATFULL
TI Compositions and methods for the treatment of burns and sepsis
IN Berenson, Ronald J., Mercer Island, WA, UNITED STATES
Bonyhadi, Mark, Issaquah, WA, UNITED STATES
PA XCYTE Therapies, Inc., Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2006286089 A1 20061221
AI US 2006-400071 A1 20060407 (11)
PRAI US 2005-669816P 20050408 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 5400, SEATTLE, WA, 98104, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 52 Drawing Page(s)
LN.CNT 4133

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to methods for treating burns and sepsis, in particular for treating immune dysfunction associated with burns and sepsis. The present invention also relates to activating and expanding T cells for the treatment of burns and sepsis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 18 OF 133 USPATFULL on STN
AN 2006:301494 USPATFULL
TI Severe acute respiratory syndrome coronavirus
IN Rappuoli, Rino, Castelnuovo Berardenga, ITALY
Masignani, Vega, Siena, ITALY
Stadler, Konrad, Scharnstein, AUSTRALIA
Gregersen, Jens Peter, Wetter, GERMANY, FEDERAL REPUBLIC OF
Chien, David, Alamo, CA, UNITED STATES
Han, Jang, Lafayette, CA, UNITED STATES
Polo, John M., Danville, CA, UNITED STATES
Weiner, Amy, Fairfield, CA, UNITED STATES
Houghton, Michael, Danville, CA, UNITED STATES
Song, Hyun Chul, Berkeley, CA, UNITED STATES
Seo, Mi-Young, Yongin-si, KOREA, REPUBLIC OF
Donnelly, John, Moraga, CA, UNITED STATES
Klenk, Hans Dieter, Marburg, GERMANY, FEDERAL REPUBLIC OF
Valiante, Nicholas, Fremont, CA, UNITED STATES
PA Chiron Corporation, Emeryville, CA, UNITED STATES (U.S. corporation)
PI US 2006257852 A1 20061116
AI US 2004-822303 A1 20040409 (10)
PRAI US 2003-462218P 20030410 (60)
US 2003-462465P 20030411 (60)
US 2003-462418P 20030412 (60)
US 2003-462748P 20030413 (60)
US 2003-463109P 20030414 (60)
US 2003-463460P 20030415 (60)
US 2003-463668P 20030416 (60)
US 2003-463983P 20030417 (60)
US 2003-463971P 20030418 (60)
US 2003-464899P 20030422 (60)
US 2003-464838P 20030422 (60)
US 2003-465273P 20030423 (60)
US 2003-465535P 20030424 (60)
US 2003-468312P 20030505 (60)
US 2003-473144P 20030522 (60)
US 2003-495024P 20030814 (60)
US 2003-505652P 20030923 (60)
US 2003-510781P 20031011 (60)
US 2003-529464P 20031211 (60)
US 2004-536177P 20040112 (60)
US 2004-560757P 20040407 (60)
DT Utility
FS APPLICATION
LREP Chiron Corporation, Intellectual Property - R440, P.O. Box 8097,
Emeryville, CA, 94662-8097, US
CLMN Number of Claims: 120
ECL Exemplary Claim: 1
DRWN 198 Drawing Page(s)
LN.CNT 30451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 19 OF 133 USPATFULL on STN
 AN 2006:247225 USPATFULL
 TI Method of treatment of a metabolic disease using intranasal administration of exendin peptide
 IN Quay, Steven C., Seattle, WA, UNITED STATES
 Leonard, Alexis Kays, Maple Valley, WA, UNITED STATES
 Costantino, Henry R., Woodinville, WA, UNITED STATES
 PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
 PI US 2006210614 A1 20060921
 AI US 2006-418982 A1 20060504 (11)
 RLI Continuation of Ser. No. US 2005-293715, filed on 2 Dec 2005, ABANDONED
 Continuation-in-part of Ser. No. US 2004-991597, filed on 18 Nov 2004, PENDING
 PRAI US 2003-532337P 20031226 (60)
 DT Utility
 FS APPLICATION
 LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906, US
 CLMN Number of Claims: 37
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Page(s)
 LN.CNT 4559
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 20 OF 133 USPATFULL on STN
 AN 2006:215041 USPATFULL
 TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, CAN-12, and variants thereof
 IN Chen, Jian, Princeton, NJ, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
 Seiler, Steven, Pennington, NJ, UNITED STATES
 Vaz, Roy J., North Branch, NJ, UNITED STATES
 Duclos, Franck, Washington Crossing, PA, UNITED STATES
 PI US 2006183196 A1 20060817
 AI US 2006-407134 A1 20060419 (11)
 RLI Division of Ser. No. US 2002-116519, filed on 3 Apr 2002, PENDING
 PRAI US 2001-281253P 20010403 (60)
 US 2001-288768P 20010504 (60)
 US 2001-296180P 20010606 (60)
 US 2001-300620P 20010625 (60)
 DT Utility
 FS APPLICATION
 LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1-23
 DRWN 27 Drawing Page(s)
 LN.CNT 29767
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and

therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 21 OF 133 USPATFULL on STN
AN 2006:174525 USPATFULL
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Bassolino, Donna A, Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2006147973 A1 20060706
US 7256267 B2 20070814
AI US 2006-329900 A1 20060111 (11)
RLI Division of Ser. No. US 2001-993180, filed on 14 Nov 2001, PENDING
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)
DT Utility
FS APPLICATION
LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1-52
DRWN 8 Drawing Page(s)
LN.CNT 18514

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 22 OF 133 USPATFULL on STN
AN 2006:174046 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2006147492 A1 20060706
AI US 2006-343809 A1 20060131 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 52

ECL Exemplary Claim: 1

DRWN 28 Drawing Page(s)

LN.CNT 56233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 23 OF 133 USPATFULL on STN

AN 2006:136908 USPATFULL

TI Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof

IN Pier, Gerald B., Brookline, MA, UNITED STATES

Kelly-Quintos, Casie Anne, Boston, MA, UNITED STATES

Cavacini, Lisa, Natick, MA, UNITED STATES

Posner, Marshall R., Medfield, MA, UNITED STATES

PA The Brigham and Women's Hospital, Inc., Boston, MA, UNITED STATES (U.S. corporation)

Beth Israel Deaconess Medical Center, Inc., Boston, MA, UNITED STATES (U.S. corporation)

PI US 2006115486 A1 20060601

AI US 2005-111688 A1 20050421 (11)

PRAI US 2004-564105P 20040421 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 15 Drawing Page(s)

LN.CNT 3365

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli.

Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 24 OF 133 USPATFULL on STN
AN 2006:87024 USPATFULL
TI Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
IN Quay, Steven C., Seattle, WA, UNITED STATES
Kleppe, Mary S., Snohomish, WA, UNITED STATES
Costantino, Henry R., Woodinville, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2006074025 A1 20060406
AI US 2005-293676 A1 20051202 (11)
RLI Continuation-in-part of Ser. No. US 2004-991597, filed on 18 Nov 2004, PENDING
PRAI US 2003-532337P 20031226 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4017

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB What is described is a pharmaceutical formulation for intranasal delivery of glucagon-like protein-1 (GLP-1), comprising an aqueous mixture of GLP-1, a solubilizing agent, a chelator, and a surface active agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 25 OF 133 USPATFULL on STN
AN 2006:81026 USPATFULL
TI Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
IN Costantino, Henry R., Woodinville, WA, UNITED STATES
Herman, Richard E., Redmond, WA, UNITED STATES
Houston, Michael E. JR., Sammamish, WA, UNITED STATES
Johnson, Paul Hickok, Snohomish, WA, UNITED STATES
Rana, Rajsharan K., Woodinville, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2006069021 A1 20060330
AI US 2005-205255 A1 20050815 (11)
PRAI US 2004-601215P 20040813 (60)
DT Utility
FS APPLICATION
LREP NASTECH PHARMACEUTICAL COMPANY INC, 3450 MONTE VILLA PARKWAY, BOTHELL, WA, 98021-8906, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 3788

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at inactive forms or parathyroid hormone peptide (PTH) or PTH analogs wherein the inactive forms are activated upon administration into the systemic circulation. Also described is a method of preventing local reaction to a biologically active agent, preparing a formulation comprising said biologically active agent, a solubilizing agent and a surfactant, and administering such formulation by contacting said

formulation with a mucosal surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 26 OF 133 USPATFULL on STN
AN 2006:15798 USPATFULL
TI Human phosphatase RET31, and variants thereof
IN Jackson, Donald G., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Suchard, Suzanne, Wilmington, DE, UNITED STATES
Schieven, Gary, Lawrenceville, NJ, UNITED STATES
Finger, Joshua, San Marcos, CA, UNITED STATES
Todderrud, C. Gordon, Newtown, PA, UNITED STATES
Bassolino, Donna, Hamilton, NJ, UNITED STATES
Krystek, Stanley, Ringoes, NJ, UNITED STATES
Banas, Dana, Hamilton, NJ, UNITED STATES
McAtee, Patrick, Pennington, NJ, UNITED STATES
PI US 2006014180 A1 20060119
AI US 2005-143984 A1 20050602 (11)
RLI Division of Ser. No. US 2001-29345, filed on 20 Dec 2001, PENDING
PRAI US 2000-256868P 20001220 (60)
US 2001-280186P 20010330 (60)
US 2001-287735P 20010501 (60)
US 2001-295848P 20010605 (60)
US 2001-300465P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 17
ECL Exemplary Claim: 1-25
DRWN 67 Drawing Page(s)
LN.CNT 29165

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 27 OF 133 USPATFULL on STN
AN 2006:3492 USPATFULL
TI Ii-key/antigenic epitope hybrid peptide vaccines
IN Humphreys, Robert, Acton, MA, UNITED STATES
Xu, Minzhen, Northborough, MA, UNITED STATES
PI US 2006002947 A1 20060105
AI US 2005-33039 A1 20050111 (11)
RLI Continuation-in-part of Ser. No. US 2002-245871, filed on 17 Sep 2002,
PENDING Continuation-in-part of Ser. No. US 2002-197000, filed on 17 Jul
2002, PENDING Division of Ser. No. US 1999-396813, filed on 14 Sep 1999,

GRANTED, Pat. No. US 6432409
DT Utility
FS APPLICATION
LREP KEVIN M. FARRELL, PIERCE ATWOOD, ONE NEW HAMPSHIRE AVENUE, SUTIE 350,
PORTSMOUTH, NH, 03801, US
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: i) immunologically neutral chemical structures, ii) a MHC Class I epitope or a portion thereof, and/or iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 28 OF 133 USPATFULL on STN
AN 2005:323977 USPATFULL
TI Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
IN Danilooff, George Y., Mountain View, CA, UNITED STATES
Sehl, Louis C., Redwood City, CA, UNITED STATES
Trollsas, Olof Mikael, San Jose, CA, UNITED STATES
Schroeder, Jacqueline, Boulder Creek, CA, UNITED STATES
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
PI US 2005281883 A1 20051222
AI US 2005-118088 A1 20050428 (11)
PRAI US 2004-566569P 20040428 (60)
DT Utility
FS APPLICATION
LREP REED INTELLECTUAL PROPERTY LAW GROUP, 1400 PAGE MILL ROAD, PALO ALTO, CA, 94304-1124, US
CLMN Number of Claims: 349
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 8347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Crosslinkable compositions are provided that readily crosslink in situ to provide crosslinked biomaterials. The composition contains at least two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. In one embodiment, a first component has nucleophilic groups and a second component has electrophilic groups. Additional components may have nucleophilic or electrophilic groups. Methods for preparing and using the compositions are also provided as are kits for delivery of the compositions. Exemplary uses for the crosslinked compositions include tissue augmentation, biologically active agent

delivery, bioadhesion, and prevention of adhesions following surgery or injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 29 OF 133 USPATFULL on STN
AN 2005:260791 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express
killer cell immunoglobulin-like receptor-like proteins
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
PA NUVELO, Inc., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 2005226812 A1 20051013
AI US 2004-962127 A1 20041008 (10)
RLI Continuation-in-part of Ser. No. WO 2004-US11171, filed on 13 Apr 2004,
PENDING Continuation-in-part of Ser. No. US 2003-727012, filed on 2 Dec
2003, PENDING Continuation-in-part of Ser. No. US 2003-414539, filed on
14 Apr 2003, ABANDONED
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 6068

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain cells, including various types of cancer cells, express KIRHy
proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for
KIRHy polypeptides and anti-KIRHy antibodies provides a method of
killing or inhibiting that growth of cancer cells that express the KIRHy
protein. Methods of therapy and diagnosis of disorders associated with
KIRHy protein-expressing cells, such as acute myelogenous leukemia
(AML), are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 30 OF 133 USPATFULL on STN
AN 2005:254894 USPATFULL
TI Molecular interactions in hematopoietic cells
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES
Schweizer, Johannes, Mountain View, CA, UNITED STATES
PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 2005221388 A1 20051006
AI US 2005-131042 A1 20050516 (11)
RLI Continuation of Ser. No. US 2000-688017, filed on 13 Oct 2000, PENDING
Continuation-in-part of Ser. No. US 2000-570118, filed on 12 May 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-570364, filed on 12
May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-569525,
filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-547276, filed on 11 Apr 2000, ABANDONED
PRAI US 2000-196460P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196267P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)
US 1999-134118P 19990514 (60)
US 1999-134117P 19990514 (60)
US 1999-134114P 19990514 (60)
DT Utility

FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834, US

CLMN Number of Claims: 20
ECL Exemplary Claim: 1-30
DRWN 14 Drawing Page(s)

LN.CNT 7797

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 31 OF 133 USPATFULL on STN

AN 2005:247674 USPATFULL

TI Molecular interactions in hematopoietic cells

IN Lu, Peter S., Mountain View, CA, UNITED STATES

Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES

Schweizer, Johannes, Mountain View, CA, UNITED STATES

PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)

PI US 2005214869 A1 20050929

AI US 2005-131054 A1 20050516 (11)

RLI Continuation of Ser. No. US 2000-688017, filed on 13 Oct 2000, PENDING
Continuation-in-part of Ser. No. US 2000-570118, filed on 12 May 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-570364, filed on 12
May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-569525,
filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-547276, filed on 11 Apr 2000, ABANDONED

PRAI US 2000-196460P 20000411 (60)

US 2000-196528P 20000411 (60)

US 2000-196527P 20000411 (60)

US 2000-196267P 20000411 (60)

US 2000-182296P 20000214 (60)

US 2000-176195P 20000114 (60)

US 1999-170453P 19991213 (60)

US 1999-162498P 19991029 (60)

US 1999-160860P 19991021 (60)

US 1999-134118P 19990514 (60)

US 1999-134117P 19990514 (60)

US 1999-134114P 19990514 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834, US

CLMN Number of Claims: 19

ECL Exemplary Claim: 1-30

DRWN 14 Drawing Page(s)

LN.CNT 7785

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 32 OF 133 USPATFULL on STN

AN 2005:240498 USPATFULL

TI Methods of therapy and diagnosis using targeting of cells that express
killer cell immunoglobulin-like receptor-like protein

IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
 Zhou, Ping, Cupertino, CA, UNITED STATES
 Asundi, Vinod, Foster City, CA, UNITED STATES
 Tang, Y. Tom, San Jose, CA, UNITED STATES
 Drmanac, Radoje T., Los Altos Hills, CA, UNITED STATES
 PA NUVELO, Inc., Sunnyvale, CA, UNITED STATES (U.S. corporation)
 PI US 2005208498 A1 20050922
 AI US 2003-727012 A1 20031202 (10)
 RLI Continuation-in-part of Ser. No. US 2003-414539, filed on 14 Apr 2003,
 ABANDONED Continuation-in-part of Ser. No. US 2000-631451, filed on 3
 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-491404,
 filed on 25 Jan 2000, ABANDONED
 PRAI WO 2001-US2623 20010125
 WO 2001-US2687 20010125
 DT Utility
 FS APPLICATION
 LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
 CLMN Number of Claims: 51
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Page(s)
 LN.CNT 4892
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Certain cells, including types of cancer cells such as KIRHy1, are
 capable of expressing KIRHy1 mRNA. Targeting using KIRHy1 polypeptides,
 nucleic acids encoding for KIRHy1 polypeptides and anti-KIRHy1
 antibodies provides a method of killing or inhibiting that growth of
 cancer cells that express the KIRHy1 protein. Methods of therapy and
 diagnosis of disorders associated with KIRHy1 protein-expressing cells,
 such as B cell lymphoma, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 33 OF 133 USPATFULL on STN
 AN 2005:229432 USPATFULL
 TI Method of determining interactions with PDZ-domain polypeptides
 IN Lu, Peter S., Mountain View, CA, UNITED STATES
 Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES
 Schweizer, Johannes, Mountain View, CA, UNITED STATES
 PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)
 PI US 6942981 B1 20050913
 AI US 2000-688017 20001013 (9)
 RLI Continuation-in-part of Ser. No. US 2000-570118, filed on 12 May 2000,
 ABANDONED Continuation-in-part of Ser. No. US 2000-570364, filed on 12
 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-569525,
 filed on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US
 2000-547276, filed on 11 Apr 2000, ABANDONED
 PRAI US 2000-196460P 20000411 (60)
 US 2000-196528P 20000411 (60)
 US 2000-196527P 20000411 (60)
 US 2000-196267P 20000411 (60)
 US 2000-182296P 20000214 (60)
 US 2000-176195P 20000114 (60)
 US 1999-170453P 19991213 (60)
 US 1999-162498P 19991029 (60)
 US 1999-160860P 19991021 (60)
 US 1999-134118P 19990514 (60)
 US 1999-134117P 19990514 (60)
 US 1999-134114P 19990514 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Chan, Christina; Assistant Examiner: Belyavskiy,
 Mikhail A
 LREP Townsend and Townsend and Crew LLP, Sandbaken, Mark G.
 CLMN Number of Claims: 8

ECL Exemplary Claim: 1
DRWN 14 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 7901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for determining interactions between multiple
PDZ-domain polypeptides and PDZ Ligand Proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 34 OF 133 USPATFULL on STN
AN 2005:226572 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,
PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1-7300
DRWN 32 Drawing Page(s)
LN.CNT 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric
compositions can be used in various medical applications including the
prevention of surgical adhesions, treatment of inflammatory arthritis,
treatment of scars and keloids, the treatment of vascular disease, and
the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 35 OF 133 USPATFULL on STN
AN 2005:220596 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005191331 A1 20050901
AI US 2004-1419 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701* FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 178

ECL Exemplary Claim: 1-2104

DRWN 28 Drawing Page(s)

LN.CNT 56419

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 36 OF 133 USPATFULL on STN

AN 2005:212065 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

PI US 2005183728 A1 20050825

AI US 2004-7836 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 178

ECL Exemplary Claim: 1-3411

DRWN 28 Drawing Page(s)

LN.CNT 56413

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants

include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L13 ANSWER 37 OF 133 USPATFULL on STN

AN 2005:209494 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005181977 A1 20050818

AI US 2004-986231 A1 20041110 (10)

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 182

ECL Exemplary Claim: 1

DRWN 28 Drawing Page(s)

LN.CNT 56396

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 38 OF 133 USPATFULL on STN

AN 2005:208533 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005181011 A1 20050818
AI US 2004-1792 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 177

ECL Exemplary Claim: 1-4994

DRWN 28 Drawing Page(s)

LN.CNT 56421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 39 OF 133 USPATFULL on STN

AN 2005:208530 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 2005181008 A1 20050818

AI US 2004-1786 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 178

ECL Exemplary Claim: 1-4736

DRWN 28 Drawing Page(s)

LN.CNT 56377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 40 OF 133 USPATFULL on STN
AN 2005:203799 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)
PI US 2005177225 A1 20050811
AI US 2004-6895 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 173
ECL Exemplary Claim: 1-11788
DRWN 28 Drawing Page(s)
LN.CNT 56371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 41 OF 133 USPATFULL on STN
AN 2005:202245 USPATFULL
TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
 PI US 2005175663 A1 20050811
 AI US 2004-1791 A1 20041202 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2003-518785P 20031110 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-525226P 20031124 (60)
 US 2003-526541P 20031203 (60)
 US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 DT Utility
 FS APPLICATION
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
 6300, SEATTLE, WA, 98104-7092, US
 CLMN Number of Claims: 180
 ECL Exemplary Claim: 1-3944
 DRWN 28 Drawing Page(s)
 LN.CNT 56451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 42 OF 133 USPATFULL on STN
 AN 2005:190568 USPATFULL
 TI Medical implants and anti-scarring agents
 IN Hunter, William L., Vancouver, CANADA
 Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Maiti, Arpita, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Liggins, Richard T., Coquitlam, CANADA
 PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)
 PI US 2005165488 A1 20050728
 AI US 2004-6912 A1 20041207 (11)
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
 PRAI US 2004-586861P 20040709 (60)
 US 2004-578471P 20040609 (60)
 US 2003-526541P 20031203 (60)
 US 2003-525226P 20031124 (60)
 US 2003-523908P 20031120 (60)
 US 2003-524023P 20031120 (60)
 US 2003-518785P 20031110 (60)
 DT Utility
 FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 176

ECL Exemplary Claim: 1-3153

DRWN 28 Drawing Page(s)

LN.CNT 56407

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L13 ANSWER 43 OF 133 USPATFULL on STN

AN 2005:189291 USPATFULL

TI Materials and methods relating to therapy and diagnosis using targeting of cells that express JPL polypeptides

IN Emtage, Peter C. R., Sunnyvale, CA, UNITED STATES

Tang, Y. Tom, San Jose, CA, UNITED STATES

Zhao, Qing A., San Jose, CA, UNITED STATES

Liu, Chenghua, San Jose, CA, UNITED STATES

Drmanac, Radoje T., Los Altos Hills, CA, UNITED STATES

PI US 2005164202 A1 20050728

AI US 2003-627373 A1 20030724 (10)

RLI Continuation-in-part of Ser. No. US 2002-293244, filed on 12 Nov 2002, PENDING Continuation-in-part of Ser. No. US 258899, ABANDONED A 371 of International Ser. No. WO 2001-US4098, filed on 5 Feb 2001
Continuation-in-part of Ser. No. US 2000-654936, filed on 1 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-560875, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed on 3 Feb 2000, ABANDONED

DT Utility

FS APPLICATION

LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 7462

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain cells, including types of cancer cells such as melanoma cells, are capable of expressing junctophilin-like (JPL) RNA. Targeting using JPL polypeptides, nucleic acids encoding for JPL polypeptides and anti-JPL antibodies provides a method of killing or inhibiting that growth of melanoma cancer cells that express the JPL protein. Targeting materials and methods for the diagnosis and therapy of melanomas that express JPL are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 44 OF 133 USPATFULL on STN

AN 2005:182941 USPATFULL

TI Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides

IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

PI US 2005158324 A1 20050721

AI US 2004-14487 A1 20041215 (11)

RLI Continuation-in-part of Ser. No. US 2003-737666, filed on 15 Dec 2003,
PENDING
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3378

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain cells, including cancer cells such as cells from cancers of the colon, breast, lung, ovary, prostate, pancreas and skin are capable of expressing BCLP. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP antibodies, peptides and small molecules provides a method of killing or inhibiting the growth of the cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of tumors that express BCLP are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 45 OF 133 USPATFULL on STN
AN 2005:172409 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005149158 A1 20050707
AI US 2004-409 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2003-518785P 20031110 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-525226P 20031124 (60)
US 2003-526541P 20031203 (60)
US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-274
DRWN 28 Drawing Page(s)
LN.CNT 56404

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 46 OF 133 USPATFULL on STN
AN 2005:172331 USPATFULL
TI Medical implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Signore, Pierre E., Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005149080 A1 20050707
AI US 2004-1418 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE
6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 178
ECL Exemplary Claim: 1-806
DRWN 28 Drawing Page(s)
LN.CNT 56418
AB Implants are used in combination with an anti-scarring agent in order to
inhibit scarring that may otherwise occur when the implant is placed
within an animal. The agent may be any suitable anti-scarring agent,
e.g., a cell cycle inhibitor, and may be used in conjunction with a
second pharmaceutical agent, e.g., an antibiotic. Suitable implants
include intravascular implants, a vascular graft or wrap implant, an
implant for hemodialysis access, an implant that provides an anastomotic
connection, ventricular assist implant, a prosthetic heart valve
implant, an inferior vena cava filter implant, a peritoneal dialysis
catheter implant, a central nervous system shunt, an intraocular lens,
an implant for glaucoma drainage, a penile implant, an endotracheal
tube, a tracheostomy tube, a gastrointestinal device, and a spinal
implant.

L13 ANSWER 47 OF 133 USPATFULL on STN
AN 2005:171269 USPATFULL
TI Novel human G-protein coupled receptor, HGPRBMY29sv1 polypeptides
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PI US 2005148016 A1 20050707
AI US 2005-70456 A1 20050302 (11)
RLI Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, PENDING
PRAI US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
US 2001-288468P 20010503 (60)
US 2001-300619P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 10

ECL Exemplary Claim: 1-20
DRWN 36 Drawing Page(s)
LN.CNT 19887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 48 OF 133 USPATFULL on STN
AN 2005:165878 USPATFULL
TI Intranasal administration of glucose-regulating peptides
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Costantino, Henry R., Woodinville, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2005143303 A1 20050630
AI US 2004-991597 A1 20041118 (10)
PRAI US 2003-532337P 20031226 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4420

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the amylin, for treating a variety of diseases and conditions in mammalian subjects, including obesity and diabetes mellitus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 49 OF 133 USPATFULL on STN
AN 2005:151374 USPATFULL
TI POLYNUCLEOTIDES ENCODING NOVEL HUMAN PHOSPHATASES
IN Jackson, Donald G., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Suchard, Suzanne, Wilmington, DE, UNITED STATES
Schieven, Gary, Lawrenceville, NJ, UNITED STATES
Finger, Joshua, San Marcos, CA, UNITED STATES
Todderrud, C. Gordon, Newtown, PA, UNITED STATES
Bassolino, Donna, Hamilton, NJ, UNITED STATES

Krystek, Stanley, Ringoes, NJ, UNITED STATES
Banas, Dana, Hamilton, NJ, UNITED STATES
McAtee, Patrick, Pennigton, NJ, UNITED STATES

PI US 2005130286 A1 20050616
US 7153678 B2 20061226
AI US 2001-29345 A1 20011220 (10)
PRAI US 2000-256868P 20001220 (60)
US 2001-280186P 20010330 (60)
US 2001-287735P 20010501 (60)
US 2001-295848P 20010605 (60)
US 2001-300465P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000, US
CLMN Number of Claims: 45
ECL Exemplary Claim: 1-25
DRWN 67 Drawing Page(s)
LN.CNT 23559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 50 OF 133 USPATFULL on STN
AN 2005:150786 USPATFULL
TI Methods of therapy and diagnosis using targeting of cells that express BCLP polypeptides
IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES
PI US 2005129697 A1 20050616
AI US 2003-737666 A1 20031215 (10)
DT Utility
FS APPLICATION
LREP NUVELO, INC, 675 ALMANOR AVE., SUNNYVALE, CA, 94085, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 3289

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain cells, including cancer cells such as cells from colon tumors, are capable of expressing BCLP RNA. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP antibodies, peptides and small molecules provides a method of killing or inhibiting the growth of colon cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of colon tumors that express BCLP are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 51 OF 133 USPATFULL on STN
AN 2005:138619 USPATFULL
TI Heterocyclic compounds and methods of making and using thereof
IN Rao, Yeleswarapu Koteswar, Hyderabad, INDIA
Pal, Manojit, Hyderabad, INDIA

Sharma, Vedula Manohar, Hyderabad, INDIA
Venkateswarlu, Akella, Hyderabad, INDIA
Pillariseti, Ram, Norcross, GA, UNITED STATES

PI US 2005119269 A1 20050602
AI US 2004-976284 A1 20041028 (10)
PRAI IN 2003-8612003 20031028
US 2004-610163P 20040915 (60)

DT Utility
FS APPLICATION

LREP WOMBLE CARLYLE SANDRIDGE & RICE, PLLC, P.O. BOX 7037, ATLANTA, GA,
30357-0037, US

CLMN Number of Claims: 59

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 13564

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I), and methods and/or compositions comprising compounds that are effective in modulating inflammatory responses, such as those resulting from AGE and glycated protein accumulation are provided. Methods and/or compositions comprising compounds that are effective in modulating smooth muscle cell proliferation and the diseases or conditions related thereto are also provided.
##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 52 OF 133 USPATFULL on STN

AN 2005:99051 USPATFULL

TI Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation

IN Berenson, Ronald J., Mercer Island, WA, UNITED STATES

Bonyhadi, Mark, Issaquah, WA, UNITED STATES

Kalamasz, Dale, Redmond, WA, UNITED STATES

PA XCYTE Therapies, Inc., Seattle, WA, UNITED STATES (U.S. corporation)

PI US 2005084967 A1 20050421

AI US 2004-900046 A1 20040727 (10)

RLI Continuation-in-part of Ser. No. US 2003-729822, filed on 5 Dec 2003,
PENDING Continuation-in-part of Ser. No. US 2003-603577, filed on 24 Jun 2003, ABANDONED

PRAI US 2003-442001P 20030122 (60)

US 2002-431212P 20021204 (60)

US 2002-393042P 20020628 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN 17 Drawing Page(s)

LN.CNT 3575

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g. autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 53 OF 133 USPATFULL on STN

AN 2005:56705 USPATFULL

TI Polynucleotides encoding a novel human neuronal cell adhesion protein,
BGS-28, and variants thereof
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
PI US 2005048620 A1 20050303
AI US 2004-926386 A1 20040825 (10)
PRAI US 2003-498170P 20030827 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 13839

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding BGS-28
polypeptides, fragments and homologues thereof. Also provided are
vectors, host cells, antibodies, and recombinant and synthetic methods
for producing said polypeptides. The invention further relates to
diagnostic and therapeutic methods for applying these novel BGS-28
polypeptides to the diagnosis, treatment, and/or prevention of various
diseases and/or disorders related to these polypeptides. The invention
further relates to screening methods for identifying agonists and
antagonists of the polynucleotides and polypeptides of the present
invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 54 OF 133 USPATFULL on STN
AN 2005:44237 USPATFULL
TI Molecular interactions in hematopoietic cells
IN Lu, Peter S., Mountain View, CA, UNITED STATES
Rabinowitz, Joshua D., Mountain View, CA, UNITED STATES
Schweizer, Johannes, Mountain View, CA, UNITED STATES
PA Arbor Vita Corporation, Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 2005037969 A1 20050217
AI US 2004-938249 A1 20040910 (10)
RLI Continuation of Ser. No. US 2000-724553, filed on 28 Nov 2000, PENDING
Continuation-in-part of Ser. No. US 2000-710059, filed on 10 Nov 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-688017, filed on 13
Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-570118, filed
on 12 May 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-570364, filed on 12 May 2000, ABANDONED Continuation-in-part of
Ser. No. US 2000-569525, filed on 12 May 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-547276, filed on 11 Apr 2000,
ABANDONED
PRAI US 2000-196460P 20000411 (60)
US 2000-196528P 20000411 (60)
US 2000-196527P 20000411 (60)
US 2000-196267P 20000411 (60)
US 2000-182296P 20000214 (60)
US 2000-176195P 20000114 (60)
US 1999-170453P 19991213 (60)
US 1999-162498P 19991029 (60)
US 1999-160860P 19991021 (60)
US 1999-134118P 19990514 (60)
US 1999-134117P 19990514 (60)
US 1999-134114P 19990514 (60)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 17

ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 10548

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 55 OF 133 USPATFULL on STN

AN 2005:36876 USPATFULL

TI Compositions and methods for enhanced mucosal delivery of growth hormone

IN Quay, Steven C., Edmonds, WA, UNITED STATES

de Meireles, Jorge C., Syosset, NY, UNITED STATES

Gupta, Malini, Dix Hills, NY, UNITED STATES

Vangala, Shyam, Dayton, OH, UNITED STATES

PA Nastech Pharmaceutical Company Inc. (U.S. corporation)

PI US 2005031549 A1 20050210

AI US 2004-862141 A1 20040601 (10)

PRAI US 2003-477403P 20030609 (60)

DT Utility

FS APPLICATION

LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell, WA, 98021-8906

CLMN Number of Claims: 70

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 4971

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical formulations are described comprising at least one growth hormone and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the growth hormone. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of growth hormone to the blood plasma, for example, by yielding a peak concentration (C.sub.max) of the growth hormone in an hepatic portal vein or a blood plasma of the subject that is 20% or greater compared to a peak concentration of the growth hormone in the hepatic portal vein or the blood plasma of the subject following administration to the subject of a same concentration or dose of the growth hormone to the subject by subcutaneous injection. Exemplary formulations and methods within the invention utilize human growth hormone as the hormone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 56 OF 133 USPATFULL on STN

AN 2005:3825 USPATFULL

TI Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity

IN Quay, Steven C., Edmonds, WA, UNITED STATES

Brandt, Gordon, Issaquah, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)

PI US 2005002927 A1 20050106

US 7186692 B2 20070306

AI US 2004-869649 A1 20040616 (10)

RLI Continuation-in-part of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING

PRAI US 2003-493226P 20030807 (60)

US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)

DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE
VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6187

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 57 OF 133 USPATFULL on STN

AN 2004:334808 USPATFULL

TI Novel human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

PI US 2004265890 A1 20041230
US 7183379 B2 20070227

AI US 2004-882761 A1 20040701 (10)

RLI Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, PENDING

PRAI US 2000-257774P 20001222 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 14389

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 58 OF 133 USPATFULL on STN

AN 2004:326844 USPATFULL

TI Compositions and methods for enhanced mucosal delivery of interferon alpha

IN Quay, Steven C., Edmonds, WA, UNITED STATES
El-Shafy, Mohammed Abd, Hauppauge, NY, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004258663 A1 20041223

AI US 2004-840536 A1 20040506 (10)
PRAI US 2003-469079P 20030508 (60)
DT Utility
FS APPLICATION
LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell,
WA, 98021-8906
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for intranasal delivery of interferon- α yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon- α is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon- α and/or a substantially decreased time to maximal concentration of interferon- α in a tissue of a subject as compared to controls where the interferon- α is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon- α according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 59 OF 133 USPATFULL on STN

AN 2004:274270 USPATFULL

TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity

IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Kingston, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc. (U.S. corporation)

PI US 2004214772 A1 20041028

US 7229966 B2 20070612

AI US 2004-780325 A1 20040217 (10)

RLI Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING

PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)

DT Utility

FS APPLICATION

LREP Nastech Pharmaceutical Company Inc., 3450 Monte Villa Parkway, Bothell,
WA, 98021-8906

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN 15 Drawing Page(s)

LN.CNT 6250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in

mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 60 OF 133 USPATFULL on STN
AN 2004:268264 USPATFULL
TI Compositions and methods for enhanced mucosal delivery of Y2
receptor-binding peptides and methods for treating and preventing
obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Brandt, Gordon, Issaquah, WA, UNITED STATES
Kleppe, Mary S., Kingston, WA, UNITED STATES
MacEvilly, Conor J., Seattle, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004209807 A1 20041021
US 7157426 B2 20070102
AI US 2004-768288 A1 20040130 (10)
RLI Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002,
PENDING
PRAI WO 2003-US40538 20031217
US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031010 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP Paul G. Lunn, Nastech Pharmaceutical Company Inc., 3450 Monte Villa
Parkway, Bothell, WA, 98021-8906
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6161

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at
least one Y2 receptor-binding peptide, such as peptide YY(PYY),
Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal
delivery-enhancing agents for enhanced nasal mucosal delivery of the
peptide YY, for treating a variety of diseases and conditions in
mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 61 OF 133 USPATFULL on STN
AN 2004:262074 USPATFULL
TI Polynucleotides encoding a novel human phosphatase, BMY_HPP13
IN Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Schieven, Gary L., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
PI US 2004204576 A1 20041014
AI US 2003-612742 A1 20030702 (10)
PRAI US 2002-393253P 20020702 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 15403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding a human phosphatase polypeptide, BMY_HPP13, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptide. The invention further relates to diagnostic and therapeutic methods for applying this novel human phosphatase polypeptide to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 62 OF 133 USPATFULL on STN

AN 2004:226988 USPATFULL

TI Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation

IN Berenson, Ronald, Mercer Island, WA, UNITED STATES

Bonyhadi, Mark, Issaquah, WA, UNITED STATES

Kalamasz, Dale, Redmond, WA, UNITED STATES

PA XCYTE Therapies, Inc., Seattle, WA (U.S. corporation)

PI US 2004175373 A1 20040909

AI US 2003-729822 A1 20031205 (10)

RLI Continuation-in-part of Ser. No. US 2003-603577, filed on 24 Jun 2003, PENDING

PRAI US 2003-442001P 20030122 (60)

US 2002-431212P 20021204 (60)

US 2002-393042P 20020628 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

CLMN Number of Claims: 67

ECL Exemplary Claim: 1

DRWN 13 Drawing Page(s)

LN.CNT 3482

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to methods for stimulating T cells, and more particularly, to methods to eliminate undesired (e.g. autoreactive, alloreactive, pathogenic) subpopulations of T cells from a mixed population of T cells, thereby restoring the normal immune repertoire of said T cells. The present invention also relates to compositions of cells, including stimulated T cells having restored immune repertoire and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 63 OF 133 USPATFULL on STN

AN 2004:203885 USPATFULL

TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity

IN Quay, Steven C., Edmonds, WA, UNITED STATES

Brandt, Gordon, Issaquah, WA, UNITED STATES

Kleppe, Mary S., Kingston, WA, UNITED STATES

MacEvilly, Conor J., Seattle, WA, UNITED STATES

PA Natestch Pharmaceutical Company Inc. (U.S. corporation)

PI US 2004157777 A1 20040812

US 7186691 B2 20070306

AI US 2003-745069 A1 20031223 (10)

RLI Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING

PRAI US 2003-493226P 20030807 (60)
US 2003-501170P 20030908 (60)
US 2003-510785P 20031008 (60)
US 2003-517290P 20031104 (60)
US 2003-518812P 20031110 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE
VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 14 Drawing Page(s)
LN.CNT 6226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at
least one Y2 receptor-binding peptide, such as peptide YY(PYY),
Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal
delivery-enhancing agents for enhanced nasal mucosal delivery of the
peptide YY, for treating a variety of diseases and conditions in
mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 64 OF 133 USPATFULL on STN
AN 2004:196400 USPATFULL
TI Compositions and methods for restoring immune repertoire in patients
with immunological defects related to autoimmunity and organ or
hematopoietic stem cell transplantation
IN Berenson, Ronald, Mercer Island, WA, UNITED STATES
Bonyhadi, Mark, Issaquah, WA, UNITED STATES
Kalamasz, Dale, Redmond, WA, UNITED STATES
PA XCYTE Therapies, Inc., Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2004151704 A1 20040805
AI US 2003-603577 A1 20030624 (10)
PRAI US 2003-442001P 20030122 (60)
US 2002-431212P 20021204 (60)
US 2002-393042P 20020628 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 3372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates generally to methods for stimulating T
cells, and more particularly, to methods to eliminate undesired (e.g.
autoreactive, alloreactive, pathogenic) subpopulations of T cells from a
mixed population of T cells, thereby restoring the normal immune
repertoire of said T cells. The present invention also relates to
compositions of cells, including stimulated T cells having restored
immune repertoire and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 65 OF 133 USPATFULL on STN
AN 2004:150914 USPATFULL
TI Compositions and methods for enhanced mucosal delivery of peptide YY and
methods for treating and preventing obesity
IN Quay, Steven C., Edmonds, WA, UNITED STATES
PI US 2004115135 A1 20040617
US 7166575 B2 20070123
AI US 2002-322266 A1 20021217 (10)

DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET
STREET, PHILADELPHIA, PA, 19103
CLMN Number of Claims: 94
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 9307

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C.sub.max) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 66 OF 133 USPATFULL on STN

AN 2004:101671 USPATFULL

TI Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds

IN Quay, Steven C., Edmonds, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc. (U.S. corporation)

PI US 2004077540 A1 20040422

AI US 2003-601953 A1 20030624 (10)

PRAI US 2002-392512P 20020628 (60)

DT Utility

FS APPLICATION

LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE
VILLA PARKWAY, BOTHELL, WA, 98021-8906

CLMN Number of Claims: 92

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 13170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject. The permeabilizing agent reversibly enhances mucosal epithelial paracellular transport, typically by modulating epithelial junctional structure and/or physiology at a mucosal epithelial surface in the subject. This effect typically involves inhibition by the permeabilizing agent of homotypic or heterotypic binding between epithelial membrane adhesive proteins of neighboring epithelial cells. Target proteins for this blockade of homotypic or heterotypic binding can be selected from various related junctional adhesion molecules (JAMs), occludins, or claudins. The permeabilizing agent is typically a peptide or peptide analog or mimetic, often selected or derived from an extracellular domain of a mammalian JAM, occludin or claudin protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 67 OF 133 USPATFULL on STN

AN 2004:77102 USPATFULL
TI Ii-key/antigenic epitope hybrid peptide vaccines
IN Humphreys, Robert E., Acton, MA, UNITED STATES
Xu, Minzhen, Northborough, MA, UNITED STATES
PA Antigen Express, Inc., Worcester, MA (U.S. corporation)
PI US 2004058881 A1 20040325
US 7179645 B2 20070220
AI US 2002-253286 A1 20020924 (10)
DT Utility
FS APPLICATION
LREP Kevin M. Farrell, Pierce Atwood, Suite 350, One New Hampshire Avenue,
Portsmouth, NH, 03801
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a nucleic acid molecule comprising a first expressible
sequence encoding a protein of interest or polypeptide of interest which
contains an MHC Class II-presented epitope. In addition, the nucleic
acid molecule comprises a second expressible nucleic acid sequence
encoding an antigen presentation enhancing hybrid polypeptide. The
antigen presentation enhancing hybrid polypeptide includes the following
elements: i) an N-terminal element consisting essentially of 4-16
residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO:
_____) and non-N-terminal deletion modifications thereof that retain
antigen presentation enhancing activity; ii) a C-terminal element
comprising an MHC Class II-presented epitope in the form of a
polypeptide or peptidomimetic structure which binds to the antigenic
peptide binding site of an MHC class II molecule, the MHC Class
II-presented epitope being contained in the protein of interest of step
a); and iii) an intervening peptidyl structure linking the N-terminal
and C-terminal elements of the hybrid, the peptidyl structure having a
length of about 20 amino acids or less.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 68 OF 133 USPATFULL on STN
AN 2004:63784 USPATFULL
TI Novel metalloprotease polypeptide, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2004048302 A1 20040311
AI US 2003-651722 A1 20030829 (10)
RLI Division of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED, Pat.
No. US 6642041
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 43 Drawing Page(s)
LN.CNT 15444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding MP-1
polypeptides, fragments and homologues thereof. Also provided are
vectors, host cells, antibodies, and recombinant and synthetic methods
for producing said polypeptides. The invention further relates to

diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 69 OF 133 USPATFULL on STN
AN 2004:57405 USPATFULL
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2004043407 A1 20040304
AI US 2003-649273 A1 20030827 (10)
RLI Continuation of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED,
Pat. No. US 6642041
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 44
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 15462

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 70 OF 133 USPATFULL on STN
AN 2004:50383 USPATFULL
TI Compositions and methods for enhanced mucosal delivery of interferon
beta
IN Quay, Steven C., Edmonds, WA, UNITED STATES
Gupta, Malini, Dix Hills, NY, UNITED STATES
de Meireles, Jorge C., Syosset, NY, UNITED STATES
Abd El-Shafy, Mohammed, Hauppauge, NY, UNITED STATES
PA Nasteck Pharmaceutical Company Inc. (U.S. corporation)
PI US 2004037809 A1 20040226
AI US 2003-462452 A1 20030616 (10)
PRAI US 2002-393066P 20020628 (60)
DT Utility
FS APPLICATION
LREP PAUL G. LUNN, ESQ. NASTECH PHARMACEUTICAL COMPANY, INC., 3450 MONTE
VILLA PARKWAY, BOTHELL, WA, 98021-8906
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 10725

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods are provided for intranasal delivery of interferon- β yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon- β is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon- β and/or a substantially decreased time to maximal concentration of interferon- β in a tissue of a subject as compared to controls where the interferon- β is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon- β according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 71 OF 133 USPATFULL on STN

AN 2004:44514 USPATFULL

TI Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof

IN Farrelly, Dennis, Monmouth Junction, NJ, UNITED STATES

Chen, Jian, Princeton, NJ, UNITED STATES

Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES

Wu, Shujian, Langhorne, PA, UNITED STATES

Bassolino, Donna A., Hamilton, NJ, UNITED STATES

Krystek, Stanley R., Ringoes, NJ, UNITED STATES

PI US 2004033506 A1 20040219

AI US 2002-308128 A1 20021202 (10)

PRAI US 2001-334904P 20011130 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 37 Drawing Page(s)

LN.CNT 28557

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding Mitochondrial GPAT, Microsomal GPAT_hlog1, Microsomal GPAT_hlog2, Microsomal GPAT_hlog3, and/or Microsomal GPAT_hlog3_v1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Mitochondrial GPAT, Microsomal GPAT_hlog1, Microsomal GPAT_hlog2, Microsomal GPAT_hlog3, and/or Microsomal GPAT_hlog3_v1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 72 OF 133 USPATFULL on STN

AN 2004:38077 USPATFULL

TI Dopamine agonist formulations for enhanced central nervous system delivery

IN Quay, Steven C., Edmonds, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)

PI US 2004028613 A1 20040212
AI US 2001-891630 A1 20010625 (9)
DT Utility
FS APPLICATION
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH
FLOOR, SAN FRANCISCO, CA, 94111-3834
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 8045

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous system (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH control agents; (d) degradative enzyme inhibitors; (e) mucolytic or mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 73 OF 133 USPATFULL on STN
AN 2004:7465 USPATFULL
TI Poroplasts
IN Surber, Mark W., Coronado, CA, UNITED STATES
Giacalone, Matthew, San Diego, CA, UNITED STATES
PI US 2004005700 A1 20040108
AI US 2002-157339 A1 20020528 (10)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18539

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 74 OF 133 USPATFULL on STN

AN 2004:7358 USPATFULL

TI Materials and methods relating to therapy and diagnosis using targeting of cells that express DCAL-Hy polypeptides

IN Emtage, Peter C.R., Sunnyvale, CA, UNITED STATES

Drmanac, Radoje T., Palo Alto, CA, UNITED STATES

Goodrich, Ryle W., Los Angeles, CA, UNITED STATES

Tang, Y. Tom, San Jose, CA, UNITED STATES

PI US 2004005592 A1 20040108

AI US 2003-379127 A1 20030303 (10)

RLI Continuation-in-part of Ser. No. US 2001-799451, filed on 5 Mar 2001, PENDING

DT Utility

FS APPLICATION

LREP NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085

CLMN Number of Claims: 51

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 7657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human DCAL-Hy polypeptides. Other aspects of the invention include vectors containing processes for producing novel human DCAL-Hy polypeptides, and antibodies specific for such polypeptides. Targeting DCAL-Hy using DCAL-Hy polypeptides, nucleic acids encoding for DCAL-Hy polypeptides, anti-DCAL-Hy antibodies, and other binding peptides and small molecules provides a method of killing or inhibiting that growth of cancer cells that express the DCAL-Hy protein. Methods of therapy and diagnosis of disorders associated with DCAL-Hy protein-expressing cells, such as DCAL-Hy, are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 75 OF 133 USPATFULL on STN

AN 2003:334718 USPATFULL

TI Ii-Key/antigenic epitope hybrid peptide vaccines

IN Humphreys, Robert, Acton, MA, UNITED STATES

Xu, Minzhen, Northborough, MA, UNITED STATES

PA Antigen Express, Inc., Worcester, MA, UNITED STATES, 01606 (U.S. corporation)

PI US 2003235594 A1 20031225

AI US 2002-245871 A1 20020917 (10)

RLI Continuation-in-part of Ser. No. US 2002-197000, filed on 17 Jul 2002, PENDING Division of Ser. No. US 1999-396813, filed on 14 Sep 1999, GRANTED, Pat. No. US 6432409

DT Utility

FS APPLICATION

LREP Kevin M. Farrell, Kevin M. Farrell, P.C., P.O. Box 999, York Harbor, ME, 03911

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 7893

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined

group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: i) immunologically neutral chemical structures, ii) a MHC Class I epitope or a portion thereof, and/or iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 76 OF 133 USPATFULL on STN
AN 2003:330124 USPATFULL
TI Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003232335 A1 20031218
AI US 2002-157317 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18564

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 77 OF 133 USPATFULL on STN
AN 2003:318700 USPATFULL
TI Antibodies to native conformations of membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003224444 A1 20031204
AI US 2002-157491 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 78 OF 133 USPATFULL on STN

AN 2003:318625 USPATFULL
TI Reverse screening and target identification with minicells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003224369 A1 20031204
AI US 2002-157171 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18610
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 79 OF 133 USPATFULL on STN
AN 2003:312291 USPATFULL
TI Minicell-based bioremediation
IN Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219888 A1 20031127
AI US 2002-157418 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 80 OF 133 USPATFULL on STN
AN 2003:311814 USPATFULL
TI Methods of making pharmaceutical compositions with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003219408 A1 20031127
AI US 2002-157320 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614

CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18632

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 81 OF 133 USPATFULL on STN

AN 2003:300375 USPATFULL

TI Minicell-based delivery agents

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES

Klepper, Robert, San Diego, CA, UNITED STATES

Surber, Mark W., Coronado, CA, UNITED STATES

PI US 2003211599 A1 20031113

AI US 2002-157106 A1 20020528 (10)

RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING

PRAI US 2002-359843P 20020225 (60)

US 2001-293566P 20010524 (60)

DT Utility

FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 18671

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 82 OF 133 USPATFULL on STN

AN 2003:299865 USPATFULL

TI Minicell-based selective absorption

IN Berkley, Neil, San Diego, CA, UNITED STATES

Sabbadini, Roger A., Lakeside, CA, UNITED STATES

PI US 2003211086 A1 20031113

AI US 2002-157073 A1 20020528 (10)

PRAI US 2001-295566P 20010605 (60)

US 2002-359843P 20020225 (60)

DT Utility

FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 18553

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 83 OF 133 USPATFULL on STN

AN 2003:294815 USPATFULL

TI Pharmaceutical compositions with minicells

IN Berkley, Neil, San Diego, CA, UNITED STATES

Klepper, Robert, San Diego, CA, UNITED STATES

Sabbadini, Roger A., Lakeside, CA, UNITED STATES

PI US 2003207833 A1 20031106

AI US 2002-156811 A1 20020528 (10)

PRAI US 2002-359843P 20020225 (60)

DT Utility

FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,

IRVINE, CA, 92614

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 18585

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 84 OF 133 USPATFULL on STN

AN 2003:289309 USPATFULL

TI Polynucleotide encoding a novel methionine aminopeptidase, protease-39

IN Chen, Jian, Princeton, NJ, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES

Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

Bassolino, Donna A., Hamilton, NJ, UNITED STATES

Krystek, Stanley R., Ringoes, NJ, UNITED STATES

Naglich, Joseph, Yardley, PA, UNITED STATES

PI US 2003204070 A1 20031030

AI US 2003-350516 A1 20030123 (10)

PRAI US 2002-351251P 20020123 (60)

US 2002-362872P 20020308 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O

BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 17388

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding Protease-39 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-39 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 85 OF 133 USPATFULL on STN

AN 2003:288723 USPATFULL

TI Conjugated minicells

IN Surber, Mark W., Coronado, CA, UNITED STATES

Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003203481 A1 20031030
AI US 2002-157213 A1 20020528 (10)
PRAI US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 86 OF 133 USPATFULL on STN
AN 2003:288653 USPATFULL
TI Methods of minicell-based delivery
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003203411 A1 20031030
AI US 2002-156792 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 87 OF 133 USPATFULL on STN
AN 2003:288179 USPATFULL
TI Minicell-based diagnostics
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003202937 A1 20031030
AI US 2002-157178 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)

LN.CNT 18527

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 88 OF 133 USPATFULL on STN

AN 2003:282746 USPATFULL

TI Membrane to membrane delivery

IN Surber, Mark W., Coronado, CA, UNITED STATES

Sabbadini, Roger A., Lakeside, CA, UNITED STATES

PI US 2003199089 A1 20031023

AI US 2002-157318 A1 20020528 (10)

PRAI US 2001-295566P 20010605 (60)

US 2002-359843P 20020225 (60)

DT Utility

FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 18530

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 89 OF 133 USPATFULL on STN

AN 2003:282745 USPATFULL

TI Minicell-based gene therapy

IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES

Berkley, Neil, San Diego, CA, UNITED STATES

Surber, Mark W., Coronado, CA, UNITED STATES

PI US 2003199088 A1 20031023

US 7183105 B2 20070227

AI US 2002-156902 A1 20020528 (10)

PRAI US 2001-295566P 20010605 (60)

US 2002-359843P 20020225 (60)

DT Utility

FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 15300

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 90 OF 133 USPATFULL on STN

AN 2003:282662 USPATFULL

TI Solid supports with minicells

IN Sabbadini, Roger, Lakeside, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES
PI US 2003199005 A1 20031023
AI US 2002-157166 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 91 OF 133 USPATFULL on STN
AN 2003:282653 USPATFULL
TI Minicell libraries
IN Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003198996 A1 20031023
AI US 2002-157147 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18482
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 92 OF 133 USPATFULL on STN
AN 2003:282652 USPATFULL
TI Forward screening with minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Gerhart, William, La Mesa, CA, UNITED STATES
PI US 2003198995 A1 20031023
AI US 2002-156831 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility

FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 93 OF 133 USPATFULL on STN
AN 2003:277136 USPATFULL
TI Polynucleotides encoding three novel human cell surface proteins with
leucine rich repeats and immunoglobulin folds, BGS2, 3, and 4 and
variants thereof
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Cheng, Janet D., Lawrenceville, NJ, UNITED STATES
PI US 2003195163 A1 20031016
US 7223558 B2 20070529
AI US 2002-193477 A1 20020711 (10)
PRAI US 2001-304888P 20010711 (60)
US 2002-372147P 20020412 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 19137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel polynucleotides encoding BGS-2, 3,
and 4 polypeptides, fragments and homologues thereof. Also provided are
vectors, host cells, antibodies, and recombinant and synthetic methods
for producing said polypeptides. The invention further relates to
diagnostic and therapeutic methods for applying these novel BGS-2, 3,
and 4 polypeptides to the diagnosis, treatment, and/or prevention of
various diseases and/or disorders related to these polypeptides. The
invention further relates to screening methods for identifying agonists
and antagonists of the polynucleotides and polypeptides of the present
invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 94 OF 133 USPATFULL on STN
AN 2003:276773 USPATFULL
TI Minicell compositions and methods
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
PI US 2003194798 A1 20031016
AI US 2002-154951 A1 20020524 (10)
PRAI US 2001-293566P 20010524 (60)
US 2002-359843P 20020225 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,

IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 95 OF 133 USPATFULL on STN
AN 2003:276689 USPATFULL
TI Minicell-based transformation
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003194714 A1 20031016
AI US 2002-157299 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)

DT Utility
FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614

CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18595

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 96 OF 133 USPATFULL on STN
AN 2003:271146 USPATFULL
TI Minicell-producing parent cells
IN Surber, Mark W., Coronado, CA, UNITED STATES
Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003190749 A1 20031009
AI US 2002-157215 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)

DT Utility
FS APPLICATION

LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614

CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 97 OF 133 USPATFULL on STN
AN 2003:271080 USPATFULL
TI Minicell-based rational drug design
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003190683 A1 20031009
AI US 2002-157302 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18539

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 98 OF 133 USPATFULL on STN
AN 2003:270998 USPATFULL
TI Target display on minicells
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PI US 2003190601 A1 20031009
AI US 2002-157096 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18581

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 99 OF 133 USPATFULL on STN
AN 2003:238122 USPATFULL
TI Minicell-based transfection
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
PI US 2003166279 A1 20030904
AI US 2002-157391 A1 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, PENDING

PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18548
AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

L13 ANSWER 100 OF 133 USPTATFULL on STN

AN 2003:237942 USPTATFULL
TI Minicells comprising membrane proteins
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Segall, Anca M., San Diego, CA, UNITED STATES
Klepper, Robert, San Diego, CA, UNITED STATES

PI US 2003166099 A1 20030904
AI US 2002-157305 A1 20020528 (10)
PRAI US 2001-295566P 20010605 (60)
US 2002-359843P 20020225 (60)

DT Utility
FS APPLICATION
LREP KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR,
IRVINE, CA, 92614
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 18580

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 101 OF 133 USPTATFULL on STN

AN 2003:225786 USPTATFULL
TI Novel human G-protein coupled receptor, HGPRBM23, expressed highly in
kidney
IN Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Cacace, Angela, Clinton, CT, UNITED STATES
Barber, Lauren, Griswold, CT, UNITED STATES
Ryseck, Rolf P., Ewing, NJ, UNITED STATES

PI US 2003157598 A1 20030821
AI US 2001-10568 A1 20011207 (10)
PRAI US 2000-251926P 20001207 (60)
US 2001-269795P 20010214 (60)

DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 42
ECL Exemplary Claim: 1

DRWN 16 Drawing Page(s)

LN.CNT 15361

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY23 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY23 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly renal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 102 OF 133 USPATFULL on STN

AN 2003:219773 USPATFULL

TI Novel human G-protein coupled receptor, HGPRBMY11, expressed highly in heart and variants thereof

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Cacace, Angela M., Clinton, CT, UNITED STATES
Barber, Lauren E., Griswood, CT, UNITED STATES

PI US 2003153063 A1 20030814

AI US 2001-991225 A1 20011116 (9)

PRAI US 2000-249613P 20001117 (60)

US 2000-257611P 20001221 (60)

US 2001-305818P 20010716 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 41

ECL Exemplary Claim: 1

DRWN 19 Drawing Page(s)

LN.CNT 16070

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY11, HGPRBMY11v1, and/or HGPRBMY11v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 103 OF 133 USPATFULL on STN

AN 2003:207348 USPATFULL

TI Novel human leucine-rich repeat containing protein expressed predominately in bone marrow, HLRRBM1

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES

PI US 2003143706 A1 20030731

AI US 2001-28374 A1 20011220 (10)

PRAI US 2000-257773P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 13850

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 104 OF 133 USPATFULL on STN
AN 2003:200810 USPATFULL
TI Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, BGS-8, expressed highly in immune tissue
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
PI US 2003138795 A1 20030724
AI US 2002-173461 A1 20020614 (10)
PRAI US 2001-298340P 20010614 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 13042

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding BGS-8 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-8 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 105 OF 133 USPATFULL on STN
AN 2003:166515 USPATFULL
TI Polynucleotide encoding a novel cysteine protease of the calpain superfamily, CAN-12, and variants thereof
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES

Vaz, Roy J., North Branch, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES

PI US 2003114373 A1 20030619
US 7186564 B2 20070306
AI US 2002-116519 A1 20020403 (10)
PRAI US 2001-281253P 20010403 (60)
US 2001-288768P 20010504 (60)
US 2001-296180P 20010606 (60)
US 2001-300620P 20010625 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 27 Drawing Page(s)
LN.CNT 30149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 106 OF 133 USPATFULL on STN

AN 2003:165871 USPATFULL
TI Human single nucleotide polymorphisms
IN Tsuchihashi, Zenta, Pennington, NJ, UNITED STATES
Hui, Lester, Fairfax, VA, UNITED STATES
Zerba, Kim, New Hope, PA, UNITED STATES
Ma-Edmonds, Manling, Lawrenceville, NJ, UNITED STATES
Perrone, Mark, Princeton, NJ, UNITED STATES
Swanson, Brian, Yardley, PA, UNITED STATES
Powell, James, Lumberville, PA, UNITED STATES

PI US 2003113726 A1 20030619
AI US 2001-5956 A1 20011203 (10)
PRAI US 2000-251015P 20001204 (60)
US 2001-263678P 20010123 (60)
US 2001-273037P 20010302 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 108 Drawing Page(s)
LN.CNT 21863

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides polynucleotides and polypeptides corresponding to novel gene sequences associated with the incidence of cardiovascular disorders. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these genes which comprise at least one polymorphic site per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which

comprise at least one polymorphic site are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, paternity testing, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly cardiovascular diseases related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 107 OF 133 USPATFULL on STN

AN 2003:140506 USPATFULL

TI Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES

PI US 2003096347 A1 20030522

US 7049096 B2 20060523

AI US 2002-120604 A1 20020411 (10)

PRAI US 2001-283145P 20010411 (60)

US 2001-283161P 20010411 (60)

US 2001-288468P 20010503 (60)

US 2001-300619P 20010625 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 36 Drawing Page(s)

LN.CNT 20308

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 108 OF 133 USPATFULL on STN

AN 2003:127127 USPATFULL

TI Novel human leucine-rich repeat containing protein expressed predominately in nervous system tissues, HLRNS1

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES

PI US 2003087340 A1 20030508
AI US 2001-28392 A1 20011220 (10)
PRAI US 2001-259479P 20010103 (60)
US 2001-260616P 20010109 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 15374

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRNS1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRNS1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly nervous system diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 109 OF 133 USPATFULL on STN

AN 2003:120301 USPATFULL
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES

PI US 2003082782 A1 20030501
US 6642041 B2 20031104
AI US 2002-67443 A1 20020205 (10)
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)

DT Utility
FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 17186

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 110 OF 133 USPATFULL on STN

AN 2003:86317 USPATFULL
TI Polynucleotide encoding a novel human potassium channel alpha-subunit,

K+alphaM1, and variants thereof
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra, Wallingford, CT, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
PI US 2003059923 A1 20030327
AI US 2001-999220 A1 20011101 (9)
PRAI US 2000-245383P 20001102 (60)
US 2000-257780P 20001221 (60)
US 2001-269854P 20010220 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 30 Drawing Page(s)
LN.CNT 16037

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding K+alphaM1 polypeptides, fragments and homologues thereof. The invention also provides novel polynucleotides encoding the K+alphaM1 variant polypeptides, K+alphaM1.v1 and K+alphaM1.v2, in addition to fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+alphaM1, K+alphaM1.v1, and K+alphaM1.v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 111 OF 133 USPATFULL on STN
AN 2003:78525 USPATFULL
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2003054445 A1 20030320
US 7247717 B2 20070724
AI US 2001-993180 A1 20011114 (9)
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 14427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 112 OF 133 USPATFULL on STN

AN 2003:45474 USPATFULL

TI Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM2

IN Chang, Han, Princeton Junction, NJ, UNITED STATES

Chen, Jian, Princeton, NJ, UNITED STATES

Feder, John, Belle Mead, NJ, UNITED STATES

Jackson, Donald, Lawrenceville, NJ, UNITED STATES

Lee, Liana, North Brunswick, NJ, UNITED STATES

Ramanathan, Chandra S., Wallingford, CT, UNITED STATES

Siemers, Nathan O., Pennington, NJ, UNITED STATES

Carroll, Pamela, Princeton, NJ, UNITED STATES

PI US 2003032786 A1 20030213

AI US 2002-56884 A1 20020124 (10)

PRAI US 2001-263872P 20010124 (60)

US 2001-269794P 20010214 (60)

DT Utility

FS APPLICATION

LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 13633

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding K+betaM2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+betaM2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 113 OF 133 USPATFULL on STN

AN 2003:45464 USPATFULL

TI Polynucleotide encoding a novel human potassium channel beta-subunit, K+Mbeta1

IN Feder, John N., Belle Mead, NJ, UNITED STATES

Lee, Liana, North Brunswick, NJ, UNITED STATES

Chen, Jian, Princeton, NJ, UNITED STATES

Jackson, Donald, Lawrenceville, NJ, UNITED STATES

Ramanathan, Chandra, Wallingford, CT, UNITED STATES

Siemers, Nathan, Pennington, NJ, UNITED STATES

Chang, Han, Princeton Junction, NJ, UNITED STATES

PI US 2003032776 A1 20030213

AI US 2001-40805 A1 20011101 (10)

PRAI US 2000-245366P 20001102 (60)
US 2000-257851P 20001221 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 12037

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding K+Mbetal polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+Mbetal polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 114 OF 133 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027161 A1 20030206
US 7074571 B2 20060711
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San
Diego, CA, 92121-1609
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 25529

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 115 OF 133 USPATFULL on STN
AN 2003:23722 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed
predominately in small intestine, HLRRS11
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES

Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PI US 2003017562 A1 20030123
US 6858407 B2 20050222
AI US 2001-29347 A1 20011220 (10)
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O
BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 14217

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 116 OF 133 USPAT2 on STN
AN 2007:224799 USPAT2
TI Polynucleotides encoding a novel human G-protein coupled receptor splice variant, HGPRBMY29SV2
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7276354 B2 20071002
AI US 2005-71761 20050303 (11)
RLI Division of Ser. No. US 2002-120604, filed on 11 Apr 2002, Pat. No. US 7049096
PRAI US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
US 2001-288468P 20010503 (60)
US 2001-300619P 20010625 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Landsman, Robert S.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 36 Drawing Figure(s); 36 Drawing Page(s)
LN.CNT 20073

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis,

treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 117 OF 133 USPAT2 on STN
AN 2006:174525 USPAT2
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A, Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES
PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7256267 B2 20070814
AI US 2006-329900 20060111 (11)
RLI Division of Ser. No. US 2001-993180, filed on 14 Nov 2001, PENDING
PRAI US 2001-282745P 20010410 (60)
US 2000-257610P 20001221 (60)
US 2000-248434P 20001114 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nashed, Nashaat T.; Assistant Examiner: Moore, William W.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 18789

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 118 OF 133 USPAT2 on STN
AN 2005:151374 USPAT2
TI Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof
IN Jackson, Donald G., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, San Francisco, CA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Suchard, Suzanne J., Wilmington, DE, UNITED STATES
Finger, Joshua, Spring City, PA, UNITED STATES
Todderud, C. Gordon, Newtown, PA, UNITED STATES
Banas, Dana, Hamilton, NJ, UNITED STATES
PA Bristol-Myers Squibb, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7153678 B2 20061226
AI US 2001-29345 20011220 (10)
PRAI US 2001-300465P 20010625 (60)

US 2001-295848P 20010605 (60)
US 2001-287735P 20010501 (60)
US 2001-280186P 20010330 (60)
US 2000-256868P 20001220 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Prouty, Rebecca E.

LREP D'Amico, Stephen C.

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 67 Drawing Figure(s); 67 Drawing Page(s)

LN.CNT 23952

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 119 OF 133 USPAT2 on STN

AN 2005:3825 USPAT2

TI Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity

IN Quay, Steven C., Edmonds, WA, UNITED STATES

Brandt, Gordon, Issaquah, WA, UNITED STATES

PA Natestch Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)

PI US 7186692 B2 20070306

AI US 2004-869649 20040616 (10)

RLI Continuation-in-part of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING

PRAI US 2003-518812P 20031110 (60)

US 2003-517290P 20031104 (60)

US 2003-510785P 20031010 (60)

US 2003-501170P 20030908 (60)

US 2003-493226P 20030807 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne

LREP Knudsen, Peter J.

CLMN Number of Claims: 50

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 6218

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 120 OF 133 USPAT2 on STN
 AN 2004:334808 USPAT2
 TI Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
 IN Feder, John N., Belle Mead, NJ, UNITED STATES
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
 Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
 PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
 PI US 7183379 B2 20070227
 AI US 2004-882761 20040701 (10)
 RLI Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, Pat. No. US 6858407
 PRAI US 2000-257774P 20001222 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Nashed, Nashaat T.
 LREP D'Amico, Stephen C.
 CLMN Number of Claims: 7
 ECL Exemplary Claim: 1
 DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
 LN.CNT 14289
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 121 OF 133 USPAT2 on STN
 AN 2004:274270 USPAT2
 TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
 IN Quay, Steven C., Edmonds, WA, UNITED STATES
 Brandt, Gordon, Issaquah, WA, UNITED STATES
 Kleppe, Mary S., Kingston, WA, UNITED STATES
 MacEvilly, Conor J., Seattle, WA, UNITED STATES
 PA Natestch Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)
 PI US 7229966 B2 20070612
 AI US 2004-780325 20040217 (10)
 RLI Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
 Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING
 PRAI US 2003-518812P 20031110 (60)
 US 2003-517290P 20031104 (60)
 US 2003-510785P 20031010 (60)
 US 2003-501170P 20030908 (60)
 US 2003-493226P 20030807 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne
 LREP Knudsen, Peter J.
 CLMN Number of Claims: 41
 ECL Exemplary Claim: 1
 DRWN 23 Drawing Figure(s); 15 Drawing Page(s)

LN.CNT 6379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 122 OF 133 USPAT2 on STN

AN 2004:268264 USPAT2

TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity

IN Quay, Steven C., Edmonds, WA, UNITED STATES

Brandt, Gordon, Issaquah, WA, UNITED STATES

Kleppe, Mary S., Kingston, WA, UNITED STATES

MacEvilly, Conor J., Seattle, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)

PI US 7157426 B2 20070102

AI US 2004-768288 20040130 (10)

RLI Continuation of Ser. No. US 2003-745069, filed on 23 Dec 2003, PENDING
Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002, PENDING

PRAI US 2003-518812P 20031110 (60)

US 2003-517290P 20031104 (60)

US 2003-510785P 20031010 (60)

US 2003-501170P 20030908 (60)

US 2003-493226P 20030807 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Kosson, Rosanne

LREP Knudsen, Peter J.

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN 20 Drawing Figure(s); 12 Drawing Page(s)

LN.CNT 6114

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 123 OF 133 USPAT2 on STN

AN 2004:203885 USPAT2

TI Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity

IN Quay, Steven C., Edmonds, WA, UNITED STATES

Brandt, Gordon, Issaquah, WA, UNITED STATES

Kleppe, Mary S., Kingston, WA, UNITED STATES

MacEvilly, Conor J., Seattle, WA, UNITED STATES

PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)

PI US 7186691 B2 20070306

AI US 2003-745069 20031223 (10)

RLI Continuation-in-part of Ser. No. US 2002-322266, filed on 17 Dec 2002,

PENDING
PRAI US 2003-518812P 20031110 (60)
US 2003-517290P 20031104 (60)
US 2003-510785P 20031010 (60)
US 2003-501170P 20030908 (60)
US 2003-493226P 20030807 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne
LREP Knudsen, Peter J.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 6193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 124 OF 133 USPAT2 on STN
AN 2004:150914 USPAT2
TI Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
IN Quay, Steven C, Edmonds, WA, UNITED STATES
PA Nastech Pharmaceutical Company Inc., Bothell, WA, UNITED STATES (U.S. corporation)
PI US 7166575 B2 20070123
AI US 2002-322266 20021217 (10)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Kosson, Rosanne
LREP Knudsen, Peter J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 12157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (C.sub.max) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 125 OF 133 USPAT2 on STN
AN 2004:77102 USPAT2
TI Ii-Key/antigenic epitope hybrid peptide vaccines
IN Humphreys, Robert E., Acton, MA, UNITED STATES
Xu, Minzhen, Northborough, MA, UNITED STATES

PA Antigen Express, Inc., Worcester, MA, UNITED STATES (U.S. corporation)
PI US 7179645 B2 20070220
AI US 2002-253286 20020924 (10)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Li, Q. Janice
LREP Pierce Atwood LLP, Farrell, Kevin M.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12901

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 126 OF 133 USPAT2 on STN

AN 2003:282745 USPAT2
TI Eubacterial minicells and their use as vectors for nucleic acid delivery and expression
IN Sabbadini, Roger A., Lakeside, CA, UNITED STATES
Berkley, Neil, San Diego, CA, UNITED STATES
Surber, Mark W., Coronado, CA, UNITED STATES
PA Vaxiion Therapeutics, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 7183105 B2 20070227
AI US 2002-156902 20020528 (10)
RLI Division of Ser. No. US 2002-154951, filed on 24 May 2002, ABANDONED
PRAI US 2002-359843P 20020225 (60)
US 2001-293566P 20010524 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Woitach, Joseph; Assistant Examiner: Kelly, Robert M.
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 21451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 127 OF 133 USPAT2 on STN
AN 2003:277136 USPAT2

TI Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunoglobulin folds, BGS2, 3, and 4 and variants thereof

IN Wu, Shujian, Langhorne, PA, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Cheng, Janet D., Lawrenceville, NJ, UNITED STATES

PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)

PI US 7223558 B2 20070529

AI US 2002-193477 20020711 (10)

PRAI US 2002-372147P 20020412 (60)
US 2001-304888P 20010711 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: O'Hara, Eileen; Assistant Examiner: Hamud, Fozia

LREP Parlet, Nickki L., D'Amico, Stephen C.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 24 Drawing Figure(s); 24 Drawing Page(s)

LN.CNT 18656

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 128 OF 133 USPAT2 on STN

AN 2003:166515 USPAT2

TI Polynucleotides encoding novel cysteine proteases of the calpain superfamily, CAN-12v1 and CAN-12v2.

IN Chen, Jian, Princeton, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Vaz, Roy J., North Branch, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES

PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)

PI US 7186564 B2 20070306

AI US 2002-116519 20020403 (10)

PRAI US 2001-300620P 20010625 (60)
US 2001-296180P 20010606 (60)
US 2001-288768P 20010504 (60)
US 2001-281253P 20010403 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Nashed, Nashaat T.; Assistant Examiner: Moore, William W.

LREP D'Amico, Stephen C.

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 27 Drawing Figure(s); 27 Drawing Page(s)

LN.CNT 30048

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention

also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 129 OF 133 USPAT2 on STN
AN 2003:140506 USPAT2
TI Polynucleotides encoding a novel human G-protein coupled receptor splice variant HGPRBMY29sv1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Hawken, Donald R., Lawrenceville, NJ, UNITED STATES
PA Bristol-Meyers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)
PI US 7049096 B2 20060523
AI US 2002-120604 20020411 (10)
PRAI US 2001-300619P 20010625 (60)
US 2001-288468P 20010503 (60)
US 2001-283145P 20010411 (60)
US 2001-283161P 20010411 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Landsman, Robert S.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 36 Drawing Figure(s); 36 Drawing Page(s)
LN.CNT 20151

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 130 OF 133 USPAT2 on STN
AN 2003:120301 USPAT2
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, United States
Feder, John N., Belle Mead, NJ, United States
Nelson, Thomas C., Lawrenceville, NJ, United States
Krystek, Stanley R., Ringoes, NJ, United States

PA Duclos, Franck, Washington Crossing, PA, United States
Bristol-Meyers Squibb Company, Princeton, NJ, United States (U.S. corporation)

PI US 6642041 B2 20031104
AI US 2002-67443 20020205 (10)
PRAI US 2001-226518P 20010205 (60)
US 2001-282814P 20010410 (60)

DT Utility
FS GRANTED

EXNAM Primary Examiner: Prouty, Rebecca E.; Assistant Examiner: Swope, Sheridan

LREP D'Amico, Stephen C.

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 18 Drawing Figure(s); 18 Drawing Page(s)

LN.CNT 16160

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 131 OF 133 USPAT2 on STN

AN 2003:78525 USPAT2

TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01

IN Chen, Jian, Princeton, NJ, UNITED STATES

Nelson, Thomas, Lawrenceville, NJ, UNITED STATES

Cheney, Daniel L., Flemington, NJ, UNITED STATES

PA Bristol-Myers Squibb Company, Princeton, NJ, UNITED STATES (U.S. corporation)

PI US 7247717 B2 20070724
AI US 2001-993180 20011114 (9)
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)

DT Utility
FS GRANTED

EXNAM Primary Examiner: Nashed, Nashaat; Assistant Examiner: Moore, William W.

LREP D'Amico, Stephen C., Mangasarian, Karen, Loring, Denise L.

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN 9 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 14304

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 132 OF 133 USPAT2 on STN
AN 2003:37516 USPAT2
TI Serine carboxypeptidase hx (SCPhx) and compositions thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA Serono Genetics Institute SA, FRANCE (non-U.S. corporation)
PI US 7074571 B2 20060711
AI US 2001-992600 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Myers, Carla J.
LREP Saliwanchik, Lloyd & Saliwanchik
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 25479

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 133 OF 133 USPAT2 on STN
AN 2003:23722 USPAT2
TI Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRSI1
IN Feder, John N., Belle Mead, NJ, United States
Ramanathan, Chandra S., Wallingford, CT, United States
Mintier, Gabriel A., Hightstown, NJ, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6858407 B2 20050222
AI US 2001-29347 20011220 (10)
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nashed, Nashaat T.
LREP D'Amico, Stephen C.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 16 Drawing Page(s)
LN.CNT 14213

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further

relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
472.75	472.96

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:21:12 ON 29 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 28 Jan 2008 (20080128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s Reiner Roland/AU
L18 63 REINER ROLAND/AU

=> s l18 and alginate
25949 ALGINATE
2412 ALGINATES
26636 ALGINATE
(ALGINATE OR ALGINATES)
L19 1 L18 AND ALGINATE

=> dis l19 bib abs

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1173498 CAPLUS
DN 143:427393
TI Injectable crosslinked and non-crosslinked alginates for use in medicine and plastic surgery
IN Reiner, Roland; Geigle, Peter; Gloeckner, Herma; Thuermer, Frank
PA CellMed A.-G., Germany
SO Ger. Offen., 9 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004019241	A1	20051103	DE 2004-102004019241	20040416
	WO 2005105167	A1	20051110	WO 2005-EP2201	20050302
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

EP 1735020 A1 20061227 EP 2005-707688 20050302
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

BR 2005009924 A 20070918 BR 2005-9924 20050302
 US 2007189114 A1 20070816 US 2007-679665 20070227
 US 2007179117 A1 20070802 US 2007-599980 20070403

PRAI DE 2004-102004019241 A 20040416
 WO 2004-EP9856 A1 20040903
 WO 2005-EP2201 W 20050302

AB The invention concerns the use of crosslinked and non-crosslinked
 alginates as volume fillers in medicine and surgery for the
 treatment of wrinkles, bladder incontinence, vesicourethral and
 gastroesophageal reflux and the support of sphincter muscles. Sodium or
 potassium alginate is crosslinked with calcium or barium ions;
 alginate and the cations can be dosed sep.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s Geigle Peter/AU
 L20 7 GEIGLE PETER/AU

=> dis l20 1-7 bib abs

L20 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1398495 CAPLUS
 TI Cultivation and differentiation of encapsulated hMSC-TERT in a disposable
 small-scale syringe-like fixed bed reactor
 AU Weber, Christian; Pohl, Sebastian; Poertner, Ralf; Wallrapp, Christine;
 Kassem, Moustapha; Geigle, Peter; Czermak, Peter
 CS Institute of Biopharmaceutical Technology, University of Applied Sciences
 Giessen-Friedberg, Giessen, Germany
 SO Open Biomedical Engineering Journal (2007), 1, 64-70
 CODEN: OBEJA6; ISSN: 1874-1207
 URL: <http://www.bentham-open.org/pages/gen.php?file=64TOBEJ.pdf&PHPSESSID=7413d61ccbel4ba77483294f60a68ba>
 PB Bentham Science Publishers Ltd.
 DT Journal; (online computer file)
 LA English
 AB The use of com. available plastic syringes is introduced as disposable
 small-scale fixed bed bioreactors for the cultivation of implantable
 therapeutic cell systems on the basis of an alginate-encapsulated human
 mesenchymal stem cell line. The system introduced is fitted with a
 noninvasive oxygen sensor for the continuous monitoring of the cultivation
 process. Fixed bed bioreactors offer advantages in comparison to other
 systems due to their ease of automation and online monitoring capability
 during the cultivation process. These benefits combined with the
 advantage of single-use make the fixed bed reactor an interesting option
 for GMP processes. The cultivation of the encapsulated cells in the fixed
 bed bioreactor system offered vitalities and adipogenic differentiation
 similar to well-mixed suspension cultures.

L20 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1398493 CAPLUS

TI Expansion and harvesting of hMSC-TERT
 AU Weber, Christian; Pohl, Sebastian; Poertner, Ralf; Wallrapp, Christine;
 Kassem, Moustapha; Geigle, Peter; Czermak, Peter
 CS Institute of Biopharmaceutical Technology, University of Applied Sciences
 Giessen-Friedberg, Giessen, Germany
 SO Open Biomedical Engineering Journal (2007), 1, 38-46
 CODEN: OBEJA6; ISSN: 1874-1207
 URL: <http://www.bentham-open.org/pages/gen.php?file=38TOBEJ.pdf&PHPSESSID=7413d61ccbela4ba77483294f60a68ba>
 PB Bentham Science Publishers Ltd.
 DT Journal; (online computer file)
 LA English
 AB The expansion of human mesenchymal stem cells as suspension culture by means of spinner flasks and microcarriers, compared to the cultivation in tissue culture flasks, offers the advantage of reducing the requirements of large incubator capacities as well as reducing the handling effort during cultivation and harvesting. Nonporous microcarriers are preferable when the cells need to be kept in viable condition for further applications like tissue engineering or cell therapy. In this study, the qualification of Biosilon, Cytodex 1, Cytodex 3, RapidCell and P102-L for expansion of hMSC-TERT with an associated harvesting process using either trypsin, accutase, collagenase or a trypsin-accutase mixture was investigated. A subsequent adipogenic differentiation of harvested hMSC-TERT was performed in order to observe possible neg. effects on their (adipogenic) differentiation potential as a result of the cultivation and harvesting method. The cultivated cells showed an average growth rate of 0.52 d-1. The cells cultivated on Biosilon, RapidCell and P102-L were harvested successfully achieving high cell yield and vitalities near 100%. This was not the case for cells on Cytodex 1 and Cytodex 3. The trypsin-accutase mix was most effective. After spinner expansion and harvesting the cells were successfully differentiated to adipocytes.

L20 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2007:1303151 CAPLUS
 DN 147:548045
 TI Spherical microcapsules comprising human mesenchymal stem cells expressing and secreting GLP-1 peptides and uses in treating diabetes
 IN Geigle, Peter; Wallrapp, Christine; Thoenes, Eric; Thuermer, Frank
 PA Biocompatibles UK Ltd., UK
 SO PCT Int. Appl., 95pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007128443	A2	20071115	WO 2007-EP3775	20070427
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1854455	A1	20071114	EP 2006-9678	20060510
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRAI EP 2006-9678 A 20060510

OS MARPAT 147:548045

AB The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present application is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapsules e.g. in the treatment of type 2 diabetes, weight disorders, neurodegenerative disorders or for the treatment of disorders and diseases or conditions associated to apoptosis. The cells contained in the core of the spherical microcapsule are selected from human mesenchymal stem cells, differentiated cells derived from human mesenchymal stem cells, including osteoblasts, chondrocytes, fat cells (adipocytes), or neuron-like cells including brain cells.

L20 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:355992 CAPLUS

DN 146:351951

TI Glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance

IN Geigle, Peter; Wallrapp, Christine; Thoenes, Eric

PA Biocompatibles UK Limited, UK

SO Eur. Pat. Appl., 55pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1767545	A1	20070328	EP 2005-20718	20050922
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	WO 2007039140	A1	20070412	WO 2006-EP9226	20060922
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2005-20718 A 20050922

AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:492867 CAPLUS

DN 144:475079

TI Method for the preparation of double-layered or multilayered microcapsules with cells

IN Thoenes, Eric; Geigle, Peter

PA CellMed A.-G., Germany

SO Ger. Offen., 7 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004055729	A1	20060524	DE 2004-102004055729	20041118
	CA 2588509	A1	20060526	CA 2005-2588509	20050922
	WO 2006053604	A1	20060526	WO 2005-EP10277	20050922
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1811978	A1	20070801	EP 2005-786032	20050922
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	DE 2004-102004055729	A	20041118		
	WO 2005-EP10277	W	20050922		

AB The invention concerns a method for the preparation double-layered or multi-layered microcapsules that are composed of microcapsule that include an inner layer and one or more outer layers; the inner layer is prepared from a crosslinked polymer and the cells; the outer layer(s) contain the same polymer but no cells. The microcapsules can be used for transplantation. The encapsulation method can also be used for other biol. active substances, e.g. drugs, cytostatics, dietary supplements instead of cells.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1173498 CAPLUS

DN 143:427393

TI Injectable crosslinked and non-crosslinked alginates for use in medicine and plastic surgery

IN Reiner, Roland; Geigle, Peter; Gloeckner, Herma; Thuermer, Frank

PA CellMed A.-G., Germany

SO Ger. Offen., 9 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004019241	A1	20051103	DE 2004-102004019241	20040416
	WO 2005105167	A1	20051110	WO 2005-EP2201	20050302
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

EP 1735020 A1 20061227 EP 2005-707688 20050302
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

BR 2005009924 A 20070918 BR 2005-9924 20050302
 US 2007189114 A1 20070816 US 2007-679665 20070227
 US 2007179117 A1 20070802 US 2007-599980 20070403

PRAI DE 2004-102004019241 A 20040416
 WO 2004-EP9856 A1 20040903
 WO 2005-EP2201 W 20050302

AB The invention concerns the use of crosslinked and non-crosslinked
 alginates as volume fillers in medicine and surgery for the treatment of
 wrinkles, bladder incontinence, vesicourethral and gastroesophageal reflux
 and the support of sphincter muscles. Sodium or potassium alginate is
 crosslinked with calcium or barium ions; alginate and the cations can be
 dosed sep.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:830598 CAPLUS

TI Procedures for operate a centrifugation unit, as well asznetrifugiereinhe
 it to accomplish such a procedure [Machine Translation].

IN Geigle, Peter

PA Geigle, Peter, Dr., 63755 Alzenau, De, Germany

SO Ger. Offen., No pp. given

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19746914	A1	19980610	DE 1997-19746914	19971023
	DE 19746914	C2	19990722		
	CA 2269607	A1	19980507	CA 1997-2269607	19971024
	CA 2269607	C	20040323		
	EP 934031	B1	20020918	EP 1997-912216	19971024
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	AT 224214	T	20021015	AT 1997-912216	19971024
	ES 2184067	T3	20030401	ES 1997-912216	19971024
PRAI	DE 1996-19644336	A1	19961025		
	WO 1997-EP5865	W	19971024		

AB Unavailable

=> s Glockner Herma/AU

L21 2 GLOCKNER HERMA/AU

=> dis l21 1-2 bib abs

L21 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:646174 CAPLUS

DN 133:247248

TI Method and device for the in vitro testing of active substances

IN Glockner, Herma; Lemke, Horst-Dieter; Meyer, Christoph

PA Akzo Nobel NV, Neth.

SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000053797	A1	20000914	WO 2000-EP2011	20000308
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1159443	A1	20011205	EP 2000-907670	20000308
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002537851	T	20021112	JP 2000-603418	20000308
PRAI	DE 1999-19910540	A	19990309		
	WO 2000-EP2011	W	20000308		

AB The invention discloses a method for the in vitro testing of active substances (e.g. cytostatic agents) in cells which includes at least the following steps: provision of a cell culture dish having an inner chamber and an outer wall as well as a first and a second membrane system positioned in the inner chamber, a cell culture chamber being configured between the membrane systems and the inner wall of the inner chamber; introduction of a cell culture and a cell culture medium into the cell culture chamber; addition of a liquid nutrient medium to the cell culture chamber; removal of products of metabolism by means of the first membrane system; delivery of at least one gaseous medium to the cell culture chamber by means of the second membrane system; addition of at least one active substance into the cell culture chamber in accordance with a set active substance concentration-time curve; and monitoring of cell vitality.

The invention also provides a device for performing the method. Use of the device for testing the effect of idarubicin on the leukemic cell line CCRF CEM is described.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:646173 CAPLUS

DN 133:205071

TI Membrane module for testing the activity of drugs on patient-specific tumor cells

IN Glockner, Herma; Lemke, Horst-Dieter; Hauck, Friedrich; Zimmerer, Christoph; Wollbeck, Rudi

PA Akzo Nobel NV, Neth.

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000053796	A1	20000914	WO 2000-EP1819	20000302
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1159444	A1	20011205	EP 2000-916893	20000302
	EP 1159444	B1	20040526		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002537850	T	20021112	JP 2000-603417	20000302
	AT 267875	T	20040615	AT 2000-916893	20000302
	ES 2220443	T3	20041216	ES 2000-916893	20000302
PRAI	DE 1999-19910539	A	19990309		

WO 2000-EP1819 W 20000302

AB The invention relates to a membrane module for testing active substances at cells, e.g. the screening of antitumor agents on tumor cells isolated from a patient. The membrane module comprises an interior space which is defined by a lid, a bottom and a side wall and houses the cell culture. A system of first capillary membranes and a system of second capillary membranes and optionally addnl. systems of capillary membranes are arranged therein. The capillary membranes in the interior space are arranged in at least one two-dimensional layer that is parallel to the bottom. A cell culturing room is configured in the interior space in the extracapillary space around the capillary membranes. The capillary membranes are provided with a lumen resp. that can be charged with a fluid. At least one end of the capillary membranes goes through the side wall of the interior space resp., is separated according to systems and is embedded into the casting compound and in such a way that the interior space is sealed off from the exterior in a fluid-proof manner. The capillary membranes of each system are fluidly connected to the lumens thereof via an inlet (7) and/or an outlet. The interior space has a volume between 0.1 and 5 cm³.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s Thurmer Frank/AU
L22 2 THURMER FRANK/AU

=> dis l22 1-2 bib abs

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:209132 CAPLUS
DN 137:237501
TI Microencapsulation-based cell therapy
AU Zimmermann, Ulrich; Cramer, Hubert; Jork, Anette; Thurmer, Frank
; Zimmermann, Heiko; Fuhr, Gunter; Hasse, Christian; Rothmund, Matthias
CS Lehrstuhl fur Biotechnologie Universitat Wurzburg Am Hubland Biozentrum,
Wurzburg, D-97074, Germany
SO Biotechnology (2nd Edition) (2001), Volume 10, 547-571. Editor(s): Rehm,
Hans-Juergen. Publisher: Wiley-VCH Verlag GmbH, Weinheim, Germany.
CODEN: 58AHA6
DT Conference; General Review
LA English
AB A review. The article focuses on the formulation of alginate-based
immunoisolation system for encapsulated cell therapy.
RE.CNT 123 THERE ARE 123 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:76857 CAPLUS
DN 137:190568
TI A novel class of amitogenic alginate microcapsules for long-term
immunoisolated transplantation
AU Zimmermann, Ulrich; Thurmer, Frank; Jork, Anette; Weber, Meike;
Mimietz, Saskia; Hillgartner, Markus; Brunnenmeier, Frank; Zimmermann,
Heiko; Westphal, Ines; Fuhr, Gunter; Noth, Ulrike; Haase, Axel; Steinert,
Andre; Hendrich, Christian
CS Lehrstuhl fur Biotechnologie, Universitat Wurzburg, Wurzburg, D-97074,
Germany
SO Annals of the New York Academy of Sciences (2001), 944(Bioartificial
Organs III), 199-215
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal
LA English
AB In the light of results of clin. trials with immunoisolated human

parathyroid tissue Ba2+-alginate capsules were developed that meet the requirements for long-term immunoisolated transplantation of (allogeneic and xenogeneic) cells and tissue fragments. Biocompatibility of the capsules was achieved by subjecting high-M alginate extracted from freshly collected brown algae to a simple purification protocol that removes quant. mitogenic and cytotoxic impurities without degradation of the alginate polymers. The final ultra-high-viscosity, clin.-grade (UHV/CG) product did not evoke any (significant) foreign body reaction in BB rats or in baboons. Similarly, the very sensitive pERK assay did not reveal any mitogenic impurities. Encapsulated cells also exhibited excellent secretory properties under in vitro conditions. Despite biocompatible material, pericapsular fibrosis is also induced by imperfect capsule surfaces that can favor cell attachment and migration under the release of material traces. This material can interact with free end monomers of the alginate polymers under formation of mitogenic advanced glycation products. Smooth surfaces, and thus topog. biocompatibility of the capsules (visualized by atomic force microscopy), can be generated by appropriate crosslinking of the UHV/CG-alginate with Ba2+ and simultaneous suppression of capsule swelling by incorporation of proteins and/or perfluorocarbons (i.e., medically approved compds. with high oxygen capacity). Perfluorocarbon-loaded alginate capsules allow long-term non-invasive monitoring of the location and the oxygen supply of the transplants by using 19F-MRI. Transplantation studies in rats demonstrated that these capsules were functional over a period of more than two years.

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis hist

(FILE 'HOME' ENTERED AT 11:00:15 ON 29 JAN 2008)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPATOLD, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, BIOSIS, EMBASE, MEDLINE' ENTERED AT 11:00:37 ON 29 JAN 2008

L1 162242 S ALGINATE
L2 45390 S L1 AND TISSUE
L3 28965 S L2 AND (AUGMENT? OR VOLUME)
L4 26601 S L3 AND INCREAS?
L5 11750 S L4 AND (CROSS(A)LINK?)
L6 2611 S L5 AND MICROPARTIC?
L7 2357 S L6 AND (CALCIUM OR BARIUM)
L8 2094 S L7 AND (SKIN OR MUSCLE OR SPHINCTER)
L9 1794 S L8 AND (EDTA OR CITRATE)
L10 1767 S L9 AND GEL
L11 800 S L9 AND HYDROGEL
L12 501 S L11 AND (SUBCUTANEOUS(S) INJECTION)
L13 133 S L12 AND (ADHESION(S) PEPTIDE)
L14 421 S L12 AND (ANTIBIOTIC OR STREPTOMYCIN)
L15 400 S L14 AND (ENGINEER? OR REPLACEMENT)
L16 333 S L15 AND ADHESION
L17 21 S L16 AND URON?

FILE 'CAPLUS' ENTERED AT 11:21:12 ON 29 JAN 2008

L18 63 S REINER ROLAND/AU
L19 1 S L18 AND ALGINATE
L20 7 S GEIGLE PETER/AU
L21 2 S GLOCKNER HERMA/AU
L22 2 S THURMER FRANK/AU